Pharmalicensing.com: PR Newswire: Clinical Trials/Medical Discoveries http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: PR Newswire: Clinical Trials/Medical Discoveries http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests SAN DIEGO, November 19 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4022 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4022 Thu, 19 Nov 2009 13:30:00 +0000 /C O R R E C T I O N -- Teva UK Ltd/ LEEDS, England, November 18 /PRNewswire/ -- In the news release, "Teva Launches TevaGrastim(R) (filgrastim)" issued on 18 Nov 2009 07:00 GMT, by Teva UK Ltd over PR Newswire, due to an omission... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4017 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4017 Wed, 18 Nov 2009 19:39:00 +0000 Hard To Treat Diseases (HTDS) Mellow Hope's H1N1 Influenza A Vaccine Successful Registration in Chile SHENZHEN, China, November 18 /PRNewswire/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China subsidiary Mellow Hope announce that they have acquired a Registration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4010 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4010 Wed, 18 Nov 2009 08:00:00 +0000 Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation GOTHENBURG, Sweden, November 18 /PRNewswire/ -- Albireo today announced the completion of a phase 1b study showing a favourable tolerability and safety profile of A3309 in patients with chronic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4011 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4011 Wed, 18 Nov 2009 08:00:00 +0000 Teva Launches TevaGrastim(R) (filgrastim) LEEDS, England, November 18 /PRNewswire/ -- Teva UK Limited has signalled its commitment to developing biosimilar medicines by entering the G-CSF* therapy area. The launch of its proprietary version... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4009 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4009 Wed, 18 Nov 2009 07:00:00 +0000 Video: Crestor(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study ORLANDO, Florida, November 17 /PRNewswire/ -- JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular (CV) events in women without... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4004 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4004 Tue, 17 Nov 2009 21:34:00 +0000 Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE PLEASANTON, California, November 17 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4001 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/4001 Tue, 17 Nov 2009 13:00:00 +0000 New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications LEIDEN, The Netherlands, November 17 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3997 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3997 Tue, 17 Nov 2009 08:00:00 +0000 Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation' SHENZHEN, China, November 17 /PRNewswire/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and Rubella... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3996 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3996 Tue, 17 Nov 2009 07:45:00 +0000 Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial ORLANDO, Florida, November 16 /PRNewswire/ -- Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3995 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3995 Mon, 16 Nov 2009 20:00:00 +0000 ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) today announced positive results from a Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3993 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3993 Mon, 16 Nov 2009 16:45:00 +0000 Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD) INGELHEIM, Germany, November 16 /PRNewswire/ -- Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3991 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3991 Mon, 16 Nov 2009 13:00:00 +0000 Medical Doctors Confirm "Divine Healing" Cases at the 6th International Christian Medical Conference KIEV, Ukraine, November 16 /PRNewswire/ -- The 6th International Christian Medical Conference was held at the President Hotel on October 30 and 31, 2009 under the auspices of Ukraine Organizing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3990 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3990 Mon, 16 Nov 2009 09:50:00 +0000 ALK Announces Landmark Asthma Prevention Trial COPENHAGEN, Denmark, November 16 /PRNewswire/ -- GAP will be the largest ever trial to investigate the asthma preventive effect of specific immunotherapy in children (5-12 years old) with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3989 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3989 Mon, 16 Nov 2009 08:00:00 +0000 New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest ORLANDO, Florida, November 15 /PRNewswire/ -- The first randomized intra-arrest cooling study performed using a novel intra-nasal cooling method showed much faster and earlier cooling in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3986 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3986 Sun, 15 Nov 2009 22:57:00 +0000 First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes ORLANDO, Florida, November 15 /PRNewswire/ -- Results from the RecordAF registry (REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation), presented today at the Scientific... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3985 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3985 Sun, 15 Nov 2009 21:00:00 +0000 Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease ORLANDO, Florida, November 15 /PRNewswire/ -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3984 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3984 Sun, 15 Nov 2009 20:00:00 +0000 Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews CAMBRIDGE, Massachusetts, November 12 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3974 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3974 Thu, 12 Nov 2009 12:00:00 +0000 Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence Finland, November 11 /PRNewswire/ -- An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3961 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3961 Wed, 11 Nov 2009 08:00:00 +0000 AMT Successful in Preclinical Treatment of DMD AMSTERDAM, November 11 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has successfully treated Duchenne... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3959 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3959 Wed, 11 Nov 2009 06:00:00 +0000 Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment LONDON, November 9 /PRNewswire/ -- Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3949 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3949 Mon, 09 Nov 2009 07:00:00 +0000 Zebinix a Novel Once Daily Anti-Epileptic Launched Today in the UK LONDON, November 9 /PRNewswire/ -- Eisai (London; Managing Director Nick Burgin), today announced that the novel once daily anti-epileptic Zebinix(R) (eslicarbazepine acetate) was launched in the UK... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3945 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3945 Mon, 09 Nov 2009 00:01:00 +0000 See the Benefits of a Healthy Lifestyle ANDOVER, England, November 9 /PRNewswire/ -- Sight charity The Eyecare Trust has joined forces with healthcare provider Simplyhealth to warn that many lifestyle choices can pose a serious threat to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3946 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3946 Mon, 09 Nov 2009 00:01:00 +0000 Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) PARIS, November 6 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3940 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3940 Fri, 06 Nov 2009 08:00:00 +0000 Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts AURORA, Ontario, November 5 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3938 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3938 Thu, 05 Nov 2009 23:08:00 +0000 Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference NOVATO, California, November 5 /PRNewswire/ -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3934 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3934 Thu, 05 Nov 2009 00:43:00 +0000 FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease CAMBRIDGE, Massachusetts, November 4 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the United States Food and Drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3928 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3928 Wed, 04 Nov 2009 12:00:00 +0000 MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 WILMINGTON, Delaware, November 3 /PRNewswire/ -- The new market research report, 'Global Stem Cell and Advanced Technologies Market' (2009 - 2014)', published by... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3923 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3923 Tue, 03 Nov 2009 09:30:00 +0000 Abbott's XIENCE PRIME(TM) and XIENCE V(R) Receive Indications in Europe for Treatment of Patients with Diabetes BRUSSELS, November 2 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that both the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus Eluting Coronary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3918 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3918 Mon, 02 Nov 2009 14:51:00 +0000 Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc. COPENHAGEN, November 2 /PRNewswire/ -- Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ. The... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3911 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3911 Mon, 02 Nov 2009 09:49:00 +0000 /C O R R E C T I O N -- CeloNova BioSciences, Inc./ NEWNAN, Georgia, October 31 /PRNewswire/ -- In the news release, French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent, issued Oct. 30, 2009, by CeloNova BioSciences, Inc.,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3908 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3908 Sat, 31 Oct 2009 00:55:00 +0000 French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent NEWNAN, Georgia, October 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene(R)-F manufactured by CeloNova... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3906 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3906 Fri, 30 Oct 2009 18:55:00 +0000 Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival LONDON, October 30 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from a recently completed Phase III study with E7389... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3898 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3898 Fri, 30 Oct 2009 08:30:00 +0000 AMT Starts Development LPLChip(TM) With Progenika AMSTERDAM, October 29 /PRNewswire/ -- Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3889 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3889 Thu, 29 Oct 2009 06:00:00 +0000 Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease DUBLIN, October 28 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3885 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3885 Wed, 28 Oct 2009 08:00:00 +0000 ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402) LEUVEN, Belgium and LUND, Sweden, October 28 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3882 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3882 Wed, 28 Oct 2009 06:30:00 +0000 BornFree Baby Bottles Borne Into Britain LONDON, October 28 /PRNewswire/ -- Parents looking to protect their babies from potentially harmful chemicals are today being advised to buy BornFree(TM), the world's leading brand for baby bottles... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3881 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3881 Wed, 28 Oct 2009 06:00:00 +0000 Simbionix Introduces the Next Generation in Bronchoscopy Training CLEVELAND, Ohio, October 27 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, introduces it's new advanced simulator, the GI-BRONCH Mentor, a comprehensive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3878 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3878 Tue, 27 Oct 2009 13:55:00 +0000 Video: One Shot of Gene Therapy and Children with Congenital Blindness Can Now See PHILADELPHIA, October 24 /PRNewswire/ -- Born with a retinal disease that made him legally blind, and would eventually leave him totally sightless, the nine-year-old boy used to sit in the back of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3860 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3860 Sat, 24 Oct 2009 19:00:00 +0000 Cohera Medical, Inc. Receives Approval To Begin Human Clinical Trials of TissuGlu(R) in Europe PITTSBURGH, October 23 /PRNewswire/ -- Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu(R) in Germany. Receipt of the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3857 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3857 Fri, 23 Oct 2009 11:53:00 +0000 Research Into Cancer During Pregnancy: Treating Pregnant Women With Chemotherapy has no Detrimental Effect on the Foetus LEUVEN, Belgium, October 23 /PRNewswire/ -- Professor Frederic Amant of the Katholieke Universiteit Leuven (K.U.Leuven) directs research into the treatment of cancer in pregnant women and the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3856 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3856 Fri, 23 Oct 2009 08:00:00 +0000 First Intra-Arrest Cooling Study Chosen for AHA Scientific Sessions Late Breaking Presentation SAN DIEGO, October 22 /PRNewswire/ -- The first randomized intra-arrest cooling study has been selected for presentation as a Late Breaking trial during the American Heart Association's Scientific... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3849 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3849 Thu, 22 Oct 2009 12:00:00 +0000 ADVANCE Reveals New Insights in the Fight Against Severe Diabetes Complications MONTREAL, October 20 /PRNewswire/ -- New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3836 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3836 Tue, 20 Oct 2009 18:00:00 +0000 Action Pharma in new Phase II Clinical Trial HOLTE, Denmark, October 20 /PRNewswire/ -- Action Pharma has initiated a new clinical phase II trial for it's leading development candidate AP214, investigating the effect of AP214 on organ... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3835 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3835 Tue, 20 Oct 2009 11:30:00 +0000 Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research PARIS, October 20 /PRNewswire/ -- Detailed results from the Prime-Boost HIV Vaccine Clinical Trial involving more than 16,000 adult volunteers in Thailand show that an investigational HIV vaccine... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3831 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3831 Tue, 20 Oct 2009 09:50:00 +0000 Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico ROCKVILLE, Maryland, October 20 /PRNewswire/ -- -- Pivotal Clinical Study to Evaluate H1N1 VLP Vaccine Safety, Immunogenicity and Efficacy in Mexico -- Novavax forms Alliance with Avimex... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3830 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3830 Tue, 20 Oct 2009 09:30:00 +0000 New Survey Shows Substantial Growth and Some Challenges with Electronic Data Capture in Clinical Trials NICE, France, October 19 /PRNewswire/ -- Preliminary findings from a new survey on electronic data capture (EDC) use in clinical trials were presented today at the Drug Information Association's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3824 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3824 Mon, 19 Oct 2009 17:45:00 +0000 EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient WELLESLEY HILLS, Massachusetts, October 16 /PRNewswire/ -- The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3819 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3819 Fri, 16 Oct 2009 18:38:00 +0000 Gynaecological Cancer Treatment Enters New era of Patient-tailored Care BELGRADE, Serbia, October 16 /PRNewswire/ -- Advances in cancer prevention and treatment reported at this week's premier European congress for specialists in gynaecological cancers show that care is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3818 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3818 Fri, 16 Oct 2009 12:08:00 +0000 Ground-Breaking Innovation: Natural Protection Against Infectious Diseases by Human-Milk-Oligosaccharide Fucosyllactose BONN and RHEINBREITBACH, Germany, October 13 /PRNewswire/ -- Human milk oligosaccharides - an important ingredient in human breast milk - play a central role in protecting infants against infection.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3801 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3801 Tue, 13 Oct 2009 12:42:00 +0000 AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy AMSTERDAM, October 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3796 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3796 Tue, 13 Oct 2009 06:00:00 +0000 Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) NOVATO, California, October 12 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3792 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3792 Mon, 12 Oct 2009 11:30:00 +0000 Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3785 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3785 Fri, 09 Oct 2009 09:00:00 +0000 New Data From the PRESTA Trial Demonstrate the Benefit of Enbrel(R) in Patients With Psoriasis and Psoriatic Arthritis MAIDENHEAD, England, October 9 /PRNewswire/ -- Data signalling that Enbrel(R) (etanercept) can improve the quality of life for people with psoriasis and psoriatic arthritis were presented at the 18th... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3784 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3784 Fri, 09 Oct 2009 08:15:00 +0000 TargetEx Leads the European Cancer Research Consortium BUDAPEST, Hungary, October 9 /PRNewswire/ -- TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3783 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3783 Fri, 09 Oct 2009 08:00:00 +0000 Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System PRINCETON, New Jersey, October 9 /PRNewswire/ -- Impliant, Inc., a developer of novel motion-sparing alternatives to traditional spinal fusion surgery, announced today that it conducted the first two... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3782 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3782 Fri, 09 Oct 2009 07:00:00 +0000 Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today DUBLIN, October 7 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3774 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3774 Wed, 07 Oct 2009 08:00:00 +0000 Clinical Genomics Continues Collaborative Research With CSIRO SYDNEY, October 7 /PRNewswire/ -- Sydney-based Clinical Genomics Pty Ltd and CSIRO have entered into a new phase in their collaboration to develop improved diagnostics for cancers of the colon and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3773 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3773 Wed, 07 Oct 2009 07:38:00 +0000 Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA AURORA, Ontario, October 6 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3770 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3770 Tue, 06 Oct 2009 14:15:00 +0000 Vantia Therapeutics' VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea Phase I Results Show VA111913 to be Safe and Well Tolerated SOUTHAMPTON, England, October 6 /PRNewswire/ -- Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3767 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3767 Tue, 06 Oct 2009 11:57:00 +0000 ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) LEUVEN, Belgium, October 5 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3759 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3759 Mon, 05 Oct 2009 17:25:00 +0000 Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement With the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers CALGARY, Canada, October 2 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has reached an agreement with the U.S. Food and Drug Administration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3749 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3749 Fri, 02 Oct 2009 13:00:00 +0000 New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure TEL-AVIV, Israel and PORTLAND, Oregon, October 2 /PRNewswire/ -- Results from a multicenter study of Cheetah Medical's Exercise Cardiac Output (ECO(R)) stress test protocol for chronic heart failure... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3748 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3748 Fri, 02 Oct 2009 12:00:00 +0000 Vital Therapies Initiates Liver Stabilization Trial SAN DIEGO, October 2 /PRNewswire/ -- Vital Therapies, Inc. (VTI), today announced that the first subject has been enrolled in a pivotal trial of its ELAD human cell-based liver assist system at... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3747 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3747 Fri, 02 Oct 2009 00:10:00 +0000 The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress TEL AVIV, Israel, October 1 /PRNewswire/ -- Dr. Worophong Manuskiatti has been invited to present results of his study "Treatment of striae distensae in skin phototypes IV-V with a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3745 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3745 Thu, 01 Oct 2009 12:16:00 +0000 Merck Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States GENEVA, September 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3739 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3739 Wed, 30 Sep 2009 18:02:00 +0000 MS Society Response to Trial Results of Novartis Multiple Sclerosis Oral Therapy FTY-720 (fingolimod) LONDON, September 30 /PRNewswire/ -- In response to today's results from pharmaceutical firm Novartis on its oral multiple sclerosis (MS) therapy FTY-720 (fingolimod), the MS Society has released the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3735 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3735 Wed, 30 Sep 2009 13:39:00 +0000 Superior Efficacy-dose Ratio for Lantus(R) Over detemir PARIS, September 30 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3732 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3732 Wed, 30 Sep 2009 07:30:00 +0000 Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers CALGARY, Canada, September 29 /PRNewswire/ -- TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase 1b/2a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3730 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3730 Tue, 29 Sep 2009 14:44:00 +0000 Blood Glucose Control Vital as Childhood Diabetes is set to Double LONDON, September 28 /PRNewswire/ -- A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3725 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3725 Mon, 28 Sep 2009 07:00:00 +0000 Neopharma Receives Approval From UAE Ministry of Health to Manufacture H1N1 Medicine DUBAI, UAE, September 28 /PRNewswire/ -- Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, today announced it has received clearance from the UAE Ministry of Health for the production of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3722 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3722 Mon, 28 Sep 2009 05:30:00 +0000 Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data CALGARY, Canada, September 25 /PRNewswire/ -- Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3721 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3721 Fri, 25 Sep 2009 18:21:00 +0000 Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union PARIS, September 25 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3720 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3720 Fri, 25 Sep 2009 17:09:00 +0000 Blackcurrants Fight Dark Circles Under Eyes LONDON, September 25 /PRNewswire/ -- Researchers in Japan have completed an intensive study which highlights the beneficial effects of blackcurrants on dark circles under the eyes. Blackcurrants... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3718 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3718 Fri, 25 Sep 2009 11:34:00 +0000 Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease SAN FRANCISCO, September 24 /PRNewswire/ -- Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3715 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3715 Thu, 24 Sep 2009 20:25:00 +0000 Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer THOUSAND OAKS, California, September 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3711 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3711 Thu, 24 Sep 2009 08:56:00 +0000 Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects BERLIN, September 24 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3710 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3710 Thu, 24 Sep 2009 08:00:00 +0000 HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV ROCKVILLE, Maryland, September 24 /PRNewswire/ -- A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3709 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3709 Thu, 24 Sep 2009 07:00:00 +0000 ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease LEUVEN, Belgium, September 24 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3708 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3708 Thu, 24 Sep 2009 06:30:00 +0000 Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial SAN FRANCISCO, September 23 /PRNewswire/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3705 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3705 Wed, 23 Sep 2009 22:08:00 +0000 Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial SAN FRANCISCO, September 23 /PRNewswire/ -- At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3704 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3704 Wed, 23 Sep 2009 19:10:00 +0000 Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer BERLIN, September 23 /PRNewswire/ -- Data from the ABCSG-24 study presented today at the joint 15th ECCO and 34th ESMO congress in Berlin, Germany, show that adding capecitabine (Xeloda(R)) to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3699 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3699 Wed, 23 Sep 2009 12:15:00 +0000 Cancer Protection Supported by UV Exposure VELDHOVEN, The Netherlands, September 23 /PRNewswire/ -- Regular, moderate UV exposure contributes to protection against breast, prostrate and colorectal cancer (colon and rectal cancer) as well as... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3696 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3696 Wed, 23 Sep 2009 08:00:00 +0000 Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis HIGH WYCOMBE, England, September 23 /PRNewswire/ -- STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3695 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3695 Wed, 23 Sep 2009 06:00:00 +0000 MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation SAN FRANCISCO, September 22 /PRNewswire/ -- Sustained reduction of mitral regurgitation following mitral valve repair with the MitraClip(R) system in patients with degenerative mitral regurgitation... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3692 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3692 Tue, 22 Sep 2009 20:00:00 +0000 Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve Repair SAN FRANCISCO, September 22 /PRNewswire/ -- The mechanical integrity of the MitraClip(R) device for repair of the mitral valve was maintained for up to five years and with complete healing, according... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3693 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3693 Tue, 22 Sep 2009 20:00:00 +0000 MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation SAN FRANCISCO, September 22 /PRNewswire/ -- Twelve-month data from EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study high-risk registry arm presented today at the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3694 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3694 Tue, 22 Sep 2009 20:00:00 +0000 Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients THOUSAND OAKS, California, September 22 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3690 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3690 Tue, 22 Sep 2009 11:55:00 +0000 New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer KVISTGAARD, Denmark, September 22 /PRNewswire/ -- Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3686 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3686 Tue, 22 Sep 2009 09:20:00 +0000 Palonosetron Effectively Prevents Emesis and Nausea Induced by High Dose Chemotherapy in Patients Undergoing Autologous Stem Cell Transplantation BERLIN, September 22 /PRNewswire/ -- New data presented today at the ECCO-ESMO joint European oncology conference in Berlin show that palonosetron, a second generation 5-HT3 receptor antagonist,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3685 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3685 Tue, 22 Sep 2009 08:30:00 +0000 Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer THOUSAND OAKS, California, September 22 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix(R) (panitumumab) in combination with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3684 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3684 Tue, 22 Sep 2009 08:28:00 +0000 Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial SAN FRANCISCO, September 21 /PRNewswire/ -- Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3679 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3679 Mon, 21 Sep 2009 16:00:00 +0000 Simbionix USA Corporation's Innovative Development Division Releases Two New Breakthrough Technologies CLEVELAND, Ohio, September 21 /PRNewswire/ -- Simbionix USA Corporation, the world's leading developer of medical simulation systems, just released two new products: a new Laparoscopic Essential... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3676 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3676 Mon, 21 Sep 2009 12:00:00 +0000 Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases THOUSAND OAKS, California, September 21 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3675 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3675 Mon, 21 Sep 2009 10:53:00 +0000 Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway HEIDELBERG, Germany, September 16 /PRNewswire/ -- Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling"** is now available online... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3661 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3661 Wed, 16 Sep 2009 19:01:00 +0000 STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial ANTONY, France, September 16 /PRNewswire/ -- Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3658 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3658 Wed, 16 Sep 2009 17:46:00 +0000 Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation SANTA CLARA, California, September 16 /PRNewswire/ -- Guided Delivery Systems, Inc. ("GDS") announced the first successful percutaneous implantation of the GDS Accucinch(R) System for mitral... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3656 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3656 Wed, 16 Sep 2009 13:45:00 +0000 Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma DENVER, Colorado and JERUSALEM, September 16 /PRNewswire/ -- Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3653 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3653 Wed, 16 Sep 2009 12:30:00 +0000 Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 MENLO PARK, California, September 15 /PRNewswire/ -- The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to take place in San Francisco from September 21-25, will serve as a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3644 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3644 Tue, 15 Sep 2009 15:00:00 +0000 Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene COLLEGEVILLE, Pennsylvania, September 15 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3642 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3642 Tue, 15 Sep 2009 13:00:00 +0000 Early Administration of Aggrenox(R) is Effective and Safe After Acute Ischaemic Stroke or TIA INGELHEIM, Germany, September 15 /PRNewswire/ -- Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3640 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3640 Tue, 15 Sep 2009 11:30:00 +0000 Results of RebiSmart(TM) User Trial Presented at 25th ECTRIMS Congress Show Broad Patient Acceptance of the New Electronic Delivery Device for Relapsing Multiple Sclerosis Treatment Rebif(R) GENEVA, September 14 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the results of the RebiSmart(TM) user trial, a Phase IIIb, multi-center, single-arm... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3633 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3633 Mon, 14 Sep 2009 16:52:00 +0000 Novant Health Rolls Out MEDai's Predictive Modeling Solution to Nine Hospitals in Three States ORLANDO, Florida, September 14 /PRNewswire/ -- MEDai, Inc., an Elsevier company and leading provider of advanced solutions for healthcare that utilize award-winning predictive analytics, announced... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3628 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3628 Mon, 14 Sep 2009 09:22:00 +0000 Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue MONTREAL and KIEL, Germany, September 14 /PRNewswire/ -- Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3627 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3627 Mon, 14 Sep 2009 09:00:00 +0000 22nd ECNP Congress 2009: are the Monoamines Involved in Shaping Conduct Disorders? ISTANBUL, Turkey, September 13 /PRNewswire/ -- New findings on the significance of platelet MAO activity and MAO gene variants with regard to antisocial behaviour have today been presented by Prof.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3623 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3623 Sun, 13 Sep 2009 09:00:00 +0000 Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time GENEVA, September 11 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the results of the complete 40-week IMPROVE (Investigating MRI Parameters with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3621 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3621 Fri, 11 Sep 2009 15:16:00 +0000 New Data From CLARITY Study on Disease Activity in MS Patients who Received Cladribine Tablets Presented at 25th ECTRIMS Congress DÜSSELDORF, Germany and GENEVA, September 11 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc analysis of the two-year... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3618 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3618 Fri, 11 Sep 2009 10:00:00 +0000 Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain LISBON, Portugal, September 11 /PRNewswire/ -- New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3616 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3616 Fri, 11 Sep 2009 08:00:00 +0000 arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work ROTTERDAM, The Netherlands, September 10 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3608 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3608 Thu, 10 Sep 2009 08:00:00 +0000 MitraClip(R) Therapy Introduced in Austria MENLO PARK, California, September 9 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3605 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3605 Wed, 09 Sep 2009 18:00:00 +0000 LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge BOZEMAN, Montana, September 8 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3592 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3592 Tue, 08 Sep 2009 11:00:00 +0000 Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for Longer MAIDENHEAD, England, September 3 /PRNewswire/ -- Patients receiving Enbrel(R) (etanercept) in combination with methotrexate for early RA are more likely to continue working, according to the COMET... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3584 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3584 Mon, 07 Sep 2009 07:00:00 +0000 Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3579 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3579 Fri, 04 Sep 2009 12:00:00 +0000 CryoLife's Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World ATLANTA, September 3 /PRNewswire/ -- More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3575 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3575 Thu, 03 Sep 2009 14:04:00 +0000 Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17 PHILADELPHIA, September 3 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3574 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3574 Thu, 03 Sep 2009 12:57:00 +0000 Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Metastases OSLO, September 3 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3572 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3572 Thu, 03 Sep 2009 07:00:00 +0000 Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 Inhibitors BARCELONA, Spain, September 2 /PRNewswire/ -- New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3564 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3564 Wed, 02 Sep 2009 07:30:00 +0000 Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RA BASEL and REINACH, Switzerland, September 2 /PRNewswire/ -- Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3563 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3563 Wed, 02 Sep 2009 07:00:00 +0000 Edoxaban - Next Generation Oral Anticoagulant Under Investigation to Help Prevent Stroke in Patients With Atrial Fibrillation BARCELONA, Spain, September 1 /PRNewswire/ -- Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3560 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3560 Tue, 01 Sep 2009 15:27:00 +0000 New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol BARCELONA, September 1 /PRNewswire/ -- Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3559 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3559 Tue, 01 Sep 2009 13:30:00 +0000 Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks BARCELONA, Spain, September 1 /PRNewswire/ -- New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to atorvastatin and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3558 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3558 Tue, 01 Sep 2009 13:00:00 +0000 MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression NATICK, Massachusetts and BARCELONA, Spain, September 1 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3548 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3548 Tue, 01 Sep 2009 07:00:00 +0000 Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials CAMBRIDGE, Massachusetts, September 1 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3549 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3549 Tue, 01 Sep 2009 07:00:00 +0000 Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes PARIS, August 31 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3539 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3539 Mon, 31 Aug 2009 09:34:00 +0000 Blood Test May Predict Course of MS LONDON, August 31 /PRNewswire/ -- Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3533 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3533 Mon, 31 Aug 2009 01:32:00 +0000 Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes PARIS, August 30 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3532 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3532 Sun, 30 Aug 2009 11:12:00 +0000 New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty PARIS, and PRINCETON, New Jersey, August 30 /PRNewswire/ -- -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3531 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3531 Sun, 30 Aug 2009 07:00:00 +0000 Bavarian Nordic A/S - Half Year Interim Report 2009 KVISTGAARD, Denmark, August 28 /PRNewswire/ -- Today Bavarian Nordic published the company's half-year interim report 2009. The full financial statements are available on the company's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3528 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3528 Fri, 28 Aug 2009 08:45:00 +0000 Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains SARASOTA, Florida, August 27 /PRNewswire/ -- Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3521 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3521 Thu, 27 Aug 2009 09:00:00 +0000 Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma MAIDENHEAD, England, August 27 /PRNewswire/ -- Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3519 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3519 Thu, 27 Aug 2009 07:00:00 +0000 Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies LACHEN, Switzerland and HOBOKEN, New Jersey, August 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3516 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3516 Wed, 26 Aug 2009 09:00:00 +0000 Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award TEL AVIV, Israel and SOUTHAMPTON, Pennsylvania, August 25 /PRNewswire/ -- Mennen Medical, a leading provider of patient monitors, cardiac catheterization and electrophysiology systems, announced... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3510 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3510 Tue, 25 Aug 2009 12:04:00 +0000 Medical World Recognises New Therapy for Reflux Babies NINOVE, Belgium, August 25 /PRNewswire/ -- 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3506 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3506 Tue, 25 Aug 2009 08:00:00 +0000 Medical World Recognises New Therapy for Reflux Babies (IRL) NINOVE, Belgium, August 25 /PRNewswire/ -- 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3507 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3507 Tue, 25 Aug 2009 08:00:00 +0000 Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform CAMBRIDGE, Massachusetts, August 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3502 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3502 Mon, 24 Aug 2009 13:00:00 +0000 Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing STOCKHOLM, August 24 /PRNewswire/ -- Karolinska Development (publ), managing one of the largest portfolios of life science research companies in Europe, announced that XSpray Microparticles AB has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3500 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3500 Mon, 24 Aug 2009 12:00:00 +0000 Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R) KVISTGAARD, Denmark, August 24 /PRNewswire/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3498 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3498 Mon, 24 Aug 2009 08:33:00 +0000 Smith & Nephew Takes Single Injection PMA to Next Stage RALEIGH and DURHAM, North Carolina, August 19 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN) Biologics & Spine is proceeding to the next stage in the approval process for the U.S. launch of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3491 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3491 Wed, 19 Aug 2009 21:54:00 +0000 Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461 SAN DIEGO, August 18 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3484 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3484 Tue, 18 Aug 2009 19:16:00 +0000 Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction WELLESLEY HILLS, Massachusetts, August 18 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3483 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3483 Tue, 18 Aug 2009 17:30:00 +0000 Clinical Study Proves Pollogen's TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks TEL AVIV, Israel, August 18 /PRNewswire/ -- Pollogen's TriPollar(TM) technology, the most advanced 3rd generation radio frequency solution for facial and body contouring, has been clinically proven... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3480 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3480 Tue, 18 Aug 2009 09:00:00 +0000 Gregorio Maranon Foundation Pioneers the Prevention of Pediatric Errors as the 1st European Installation of i.v.STATION(TM) BOZEN, Italy, August 17 /PRNewswire/ -- Health Robotics today announced that it has reached an agreement with Gregorio Maranon Foundation to sell and install its revolutionary i.v.STATION robot at... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3474 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3474 Mon, 17 Aug 2009 14:00:00 +0000 D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE) REHOVOT, Israel, August 17 /PRNewswire/ -- D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3473 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3473 Mon, 17 Aug 2009 13:00:00 +0000 New Consortium to Develop Drugs for Neglected Tropical Diseases LEIDEN, The Netherlands, August 17 /PRNewswire/ -- A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3472 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3472 Mon, 17 Aug 2009 08:00:00 +0000 Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial PALO ALTO, California, August 10 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3453 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3453 Mon, 10 Aug 2009 13:30:00 +0000 CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research EINDHOVEN, The Netherlands, August 4 /PRNewswire/ -- With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3435 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3435 Tue, 04 Aug 2009 10:33:00 +0000 Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy Than Chlorambucil in CLL CAMBRIDGE, England, August 4 /PRNewswire/ -- Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3434 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3434 Tue, 04 Aug 2009 08:00:00 +0000 The European Commission Approves Samsca(TM) (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) TOKYO, Japan and UXBRIDGE, England, August 3 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that the European Commission has approved... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3433 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3433 Mon, 03 Aug 2009 20:00:00 +0000 Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA LEXINGTON, Massachusetts, August 3 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3430 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3430 Mon, 03 Aug 2009 07:00:00 +0000 British Woman Celebrates a Year of Living Cancer-Free LONDON, July 31 /PRNewswire/ -- It's been a year since fashion designer Joanne Scott went through a cancer treatment that changed her life -- and made history to boot. Ms Scott, 54, was the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3426 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3426 Fri, 31 Jul 2009 00:05:00 +0000 Royal Pharmaceutical Society Calls for Older People to Review Their Medicine With a Pharmacist LONDON, July 29 /PRNewswire/ -- New research released today by the Royal Pharmaceutical Society of Great Britain (RPSGB) reveals how older people are taking a cocktail of medicine without fully... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3419 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3419 Tue, 28 Jul 2009 11:51:00 +0000 FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents PHILADELPHIA, July 28 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3413 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3413 Tue, 28 Jul 2009 07:00:00 +0000 Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts KEELE, England, July 27 /PRNewswire/ -- A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, ( http://www.biocomposites.com),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3410 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3410 Mon, 27 Jul 2009 13:00:00 +0000 Movetis Receives Positive Opinion by the CHMP on European Marketing Authorisation Application for Resolor(R) (prucalopride) Indicated for the Treatment of Chronic Constipation TURNHOUT, Belgium, July 27 /PRNewswire/ -- Movetis, the GI specialty pharmaceutical company based in Belgium announces today that it has received a positive opinion from the Committee for Medicinal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3409 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3409 Mon, 27 Jul 2009 11:00:00 +0000 European CHMP Issues Positive Opinion on Wyeth's TORISEL for Treatment of Relapsed/Refractory Mantle Cell Lymphoma MAIDENHEAD, England, July 27 /PRNewswire/ -- Wyeth Europa, a division of Wyeth (NYSE:WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3408 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3408 Mon, 27 Jul 2009 10:11:00 +0000 Ilaris(R) Recommended for European Approval as New Biologic Drug to Treat a Rare but Serious Group of Auto-Inflammatory Diseases BASEL, Switzerland, July 24 /PRNewswire/ -- The biotechnology medicine Ilaris(R) (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3405 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3405 Fri, 24 Jul 2009 14:36:00 +0000 Approval of Instanyl(R) Marks Important Turn in Management of Breakthrough Cancer Pain TAASTRUP, Denmark, July 24 /PRNewswire/ -- Nycomed today announced that the European Commission has granted marketing authorisation for Instanyl, its first-in-class intranasal fentanyl spray designed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3404 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3404 Fri, 24 Jul 2009 09:15:00 +0000 Merck Serono Submits Application for Cladribine Tablets as Multiple Sclerosis Therapy in Europe GENEVA, Switzerland, July 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a marketing authorization application (MAA) to the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3399 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3399 Thu, 23 Jul 2009 07:30:00 +0000 Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says WASHINGTON, July 21 /PRNewswire/ -- Clinical trials conducted in the developing world meet the same safety, ethical and quality standards as those conducted in the developed world. That is the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3394 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3394 Tue, 21 Jul 2009 13:00:00 +0000 Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3388 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3388 Mon, 20 Jul 2009 05:01:00 +0000 BRAHMS KRYPTOR Compact is Certified by the Fetal Medicine Foundation (FMF) HENNIGSDORF, Germany, July 17 /PRNewswire/ -- The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening. ... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3387 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3387 Fri, 17 Jul 2009 15:43:00 +0000 Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease LEXINGTON, Massachusetts, July 16 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the U.S.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3378 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3378 Thu, 16 Jul 2009 07:00:00 +0000 Canadian Researchers Discover Gene Related to the Appearance of Aging HALIFAX, Canada, July 15 /PRNewswire/ -- Scientists in Atlantic Canada have found a gene that may play a role in skin aging. Researchers were investigating the genetic cause of a rare disorder known... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3376 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3376 Wed, 15 Jul 2009 18:21:00 +0000 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing BOSTON and EDISON, New Jersey, July 15 /PRNewswire/ -- -- Pharmacokinetic Analysis of Atrial Fibrillation Study May Explain Bleeding Rate Difference between Once-Daily and Twice-Daily Dosing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3373 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3373 Wed, 15 Jul 2009 13:30:00 +0000 Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease VIENNA, July 14 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) presented information this week at the Alzheimer Association 2009 International Conference on Alzheimer's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3363 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3363 Tue, 14 Jul 2009 14:00:00 +0000 Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease BROOMFIELD, Colorado, July 14 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced further evidence for genetic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3360 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3360 Tue, 14 Jul 2009 12:08:00 +0000 A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders TIRAT CARMEL, Israel, July 14 /PRNewswire/ -- InSightec Ltd. today announced that a team at the University Children's Hospital Zurich has completed a feasibility study testing the use of non-invasive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3358 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3358 Tue, 14 Jul 2009 08:35:00 +0000 Sirius Genomics Announces New Collaboration With Assistance Publique-Hopitaux de Paris VANCOUVER, Canada, July 13 /PRNewswire/ -- Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with the Assistance... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3352 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3352 Mon, 13 Jul 2009 10:00:00 +0000 Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3344 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3344 Wed, 08 Jul 2009 13:37:00 +0000 Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System AARHUS, Denmark, July 7 /PRNewswire/ -- Unisense FertiliTech A/S ( http://www.fertilitech.com) announces that the EmbryoScope(TM) Embryo Monitoring System and EmbryoSlide(TM) tray have received CE... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3337 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3337 Tue, 07 Jul 2009 09:00:00 +0000 Sanofi Pasteur Files for Approval in Thailand and Australia of IMOJEV(TM), Single-dose Japanese Encephalitis Vaccine LYON, France, July 7 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis group, (EURONEXT: SAN and NYSE: SNY), announced today that it has filed marketing authorization... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3334 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3334 Tue, 07 Jul 2009 07:00:00 +0000 Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease LEXINGTON, Massachusetts, July 6 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3332 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3332 Mon, 06 Jul 2009 20:01:00 +0000 New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3330 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3330 Mon, 06 Jul 2009 12:00:00 +0000 Sigma-tau Submits Marketing Authorization Application to EMEA for a Novel Anti-Malarial ROME, July 6 /PRNewswire/ -- Sigma-tau Industrie Farmaceutiche Riunite S.p.A. (sigma-tau) has announced the submission of a centralized Marketing Authorization Application (MAA) to the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3329 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3329 Mon, 06 Jul 2009 08:00:00 +0000 ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3325 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3325 Fri, 03 Jul 2009 06:30:00 +0000 Latest Guidance Issued by BTS/SIGN Supports use of Single Inhaler for Maintenance and Relief in Asthmatic Patients LONDON, July 2 /PRNewswire/ -- Updated guidelines issued this week by the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) include the use... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3322 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3322 Thu, 02 Jul 2009 13:00:00 +0000 FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter PARIS, July 2 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3320 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3320 Thu, 02 Jul 2009 09:04:00 +0000 New Review on PROSTVAC(TM) Published by Key Investigators From NCI KVISTGAARD, Denmark, July 1 /PRNewswire/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3319 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3319 Wed, 01 Jul 2009 15:20:00 +0000 /C O R R E C T I O N -- Enigma Diagnostics Limited/ PORTON DOWN, England, June 30 /PRNewswire/ -- In the news release, "Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency" issued on 30 Jun... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3311 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3311 Tue, 30 Jun 2009 15:43:00 +0000 Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency PORTON DOWN, England, June 30 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3309 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3309 Tue, 30 Jun 2009 14:17:00 +0000 Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases SAN DIEGO, June 30 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3308 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3308 Tue, 30 Jun 2009 14:00:00 +0000 Supportive Care in Cancer: Palonosetron Recommended 5-HT3 Antagonist for Emesis Prevention by MASCC/ESMO LUGANO, Switzerland, June 30 /PRNewswire/ -- About Palonosetron (Aloxi(R), Onicit(R), Paloxi(R)) Palonosetron (palonosetron hydrochloride) is a selective 5-HT3 receptor antagonist, developed for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3307 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3307 Tue, 30 Jun 2009 13:52:00 +0000 New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF AMSTERDAM, The Netherlands, June 30 /PRNewswire/ -- New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3302 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3302 Tue, 30 Jun 2009 09:00:00 +0000 Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3295 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3295 Mon, 29 Jun 2009 09:55:00 +0000 Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3292 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3292 Mon, 29 Jun 2009 06:00:00 +0000 The Impact of Financing Mechanisms on Patient Access to Innovation - EHTI Presents Research Findings BRUSSELS and INNSBRUCK, Austria, June 26 /PRNewswire/ -- One of the questions the European Health Technology Institute for Socio-Economic Research (EHTI) hopes to answer is whether national... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3287 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3287 Fri, 26 Jun 2009 09:15:00 +0000 Second Generation 5-HT3 Antagonists Open New Perspectives in Emesis Prevention ROME, June 25 /PRNewswire/ -- The MASCC (Multinational Association of Supportive Care in Cancer) 2009 International Symposium opens today in Rome, Italy - Chemotherapy-induced nausea and vomiting... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3279 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3279 Thu, 25 Jun 2009 11:05:00 +0000 ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule LEUVEN, Belgium, June 25 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3278 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3278 Thu, 25 Jun 2009 06:30:00 +0000 Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials MUMBAI, India, June 24 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3276 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3276 Wed, 24 Jun 2009 14:58:00 +0000 Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy CHARLOTTESVILLE, Virginia, June 24 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3269 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3269 Wed, 24 Jun 2009 09:00:00 +0000 Merck Serono Launches RebiSmart(TM), First Electronic Injection Device for Delivery of Multiple Sclerosis Treatment Rebif(R) GENEVA, June 24 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3271 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3271 Wed, 24 Jun 2009 09:00:00 +0000 Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3273 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3273 Wed, 24 Jun 2009 09:00:00 +0000 Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3265 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3265 Tue, 23 Jun 2009 13:00:00 +0000 New Data From CLARITY Study Presented at 19th ENS Meeting Show Rapid and Sustained MS Relapse Reduction for Cladribine Tablets MILAN, Italy and GENEVA, Switzerland, June 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today new data from post-hoc analyses of the 2-year... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3254 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3254 Mon, 22 Jun 2009 13:30:00 +0000 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) SAN MATEO, California and STAINES, England, June 22 /PRNewswire/ -- NeurogesX, Inc. (NASDAQ: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3252 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3252 Mon, 22 Jun 2009 12:00:00 +0000 New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development DUBLIN, June 18 /PRNewswire/ -- According to a report issued today, drug safety leaders in pharmaceutical and biotechnology companies recognise the need to increase resources, either internally or... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3241 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3241 Thu, 18 Jun 2009 08:00:00 +0000 ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM) SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ -- ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3240 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3240 Thu, 18 Jun 2009 07:00:00 +0000 Glybera(TM) Shows Long-Term Health Benefits AMSTERDAM, The Netherlands, June 18 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today new data showing that a one-time... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3239 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3239 Thu, 18 Jun 2009 06:00:00 +0000 BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device LAVAL, Canada, June 17 /PRNewswire/ -- BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced statistically significant... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3236 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3236 Wed, 17 Jun 2009 14:49:00 +0000 Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia OSLO, Norway, June 17 /PRNewswire/ -- Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3235 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3235 Wed, 17 Jun 2009 13:39:00 +0000 Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy TEL AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3231 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3231 Wed, 17 Jun 2009 10:52:00 +0000 Study Demonstrates Efficacy of Pitavastatin in Elderly Patients BOSTON, June 16 /PRNewswire/ -- New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidaemia in elderly patients, with a similar safety and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3227 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3227 Tue, 16 Jun 2009 13:00:00 +0000 MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes ROCKVILLE, Maryland and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the PROTEGE trial achieved its targeted patient enrollment.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3224 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3224 Tue, 16 Jun 2009 12:00:00 +0000 Eli Lilly and Company Announces New Drug Discovery Initiative INDIANAPOLIS, June 15 /PRNewswire/ -- Alzheimer's disease. Cancer. Diabetes. Osteoporosis. These are the diseases for which Eli Lilly and Company will be engaging researchers from around the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3217 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3217 Mon, 15 Jun 2009 14:47:00 +0000 Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction BOSTON, June 15 /PRNewswire/ -- New data presented today showed that pitavastatin may provide a new treatment option for patients with dyslipidaemia and complex issues, such as those on multiple... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3214 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3214 Mon, 15 Jun 2009 13:00:00 +0000 UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients PITTSBURGH, Pennsylvania, and JERUSALEM, Israel, June 15 /PRNewswire/ -- The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3213 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3213 Mon, 15 Jun 2009 12:00:00 +0000 Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism (EULAR) Annual Meeting MAIDENHEAD, England, June 12 /PRNewswire/ -- Analyses of data from three studies provide insight into the use of ENBREL(R) (etanercept) in the treatment of three conditions for which ENBREL is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3206 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3206 Fri, 12 Jun 2009 09:15:00 +0000 Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four Years BRUSSELS, June 12 /PRNewswire/ -- Clinical data presented this week at the 13th International Congress of Parkinson's Disease and Movement Disorders in Paris, France showed rotigotine improved early... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3204 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3204 Fri, 12 Jun 2009 06:00:00 +0000 New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease COLLEGEVILLE, Pennsylvania, June 11 /PRNewswire/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3198 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3198 Thu, 11 Jun 2009 12:00:00 +0000 Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3195 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3195 Thu, 11 Jun 2009 09:00:00 +0000 ChemGenex's Omacetaxine Shows Activity in Refractory CML LONDON, June 9 /PRNewswire/ -- ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3184 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3184 Tue, 09 Jun 2009 17:54:00 +0000 Ipsat Announces Positive Data on a Novel Therapy Designed to Reduce Healthcare-associated Infections and the Spread of Antibiotic Resistance HELSINKI, June 8 /PRNewswire/ -- Ipsat Therapies announced today that oral P1A beta-lactamase met all end-points and provided protection for the normal gastrointestinal microflora in a phase 1 study... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3172 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3172 Mon, 08 Jun 2009 08:00:00 +0000 AF AWARE Cardiology Groups Call for Greater Awareness and Better Education on Atrial Fibrillation LONDON, June 8 /PRNewswire/ -- Survey Shows Many Doctors Find the Management of Atrial Fibrillation Difficult and Patients are Unaware of the Risks, Complexities and Treatment for This Most Common of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3171 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3171 Mon, 08 Jun 2009 07:30:00 +0000 New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP BERLIN, June 7 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3169 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3169 Sun, 07 Jun 2009 08:56:00 +0000 New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results INGELHEIM, Germany, June 6 /PRNewswire/ -- Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting (ADA) show clinically... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3168 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3168 Sat, 06 Jun 2009 16:00:00 +0000 Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non Hodgkin's Lymphoma Patients BERLIN, Germany, June 5 /PRNewswire/ -- New data presented today at the EHA (European Haematology Association) Congress in Berlin show that a single dose of palonosetron, a second generation 5-HT3... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3165 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3165 Fri, 05 Jun 2009 09:00:00 +0000 Advance in Bowel Cancer Test Research SYDNEY, June 5 /PRNewswire/ -- Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3163 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3163 Fri, 05 Jun 2009 00:15:00 +0000 Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device MAIDENHEAD, England, June 4 /PRNewswire/ -- Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3160 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3160 Thu, 04 Jun 2009 07:00:00 +0000 One-Year Phase III Study Confirms Ilaris(R) Offers Long-Term Remission in Patients With CAPS, a Severe Lifelong Auto-Inflammatory Disease BASEL, Switzerland, June 3 /PRNewswire/ -- New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris(R) (canakinumab, formerly ACZ885)[*] produced... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3158 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3158 Wed, 03 Jun 2009 22:00:00 +0000 Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons SUNNYVALE, California, June 3 /PRNewswire/ -- Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3157 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3157 Wed, 03 Jun 2009 18:00:00 +0000 Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival PARIS and BRISBANE, California, June 3 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3156 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3156 Wed, 03 Jun 2009 15:35:00 +0000 First Phase III Clinical Trial Results of Safinamide in Advanced Parkinson's Disease to Be Presented at the Movement Disorder Society 13th International Congress GENEVA, Switzerland, June 3 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that detailed results... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3154 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3154 Wed, 03 Jun 2009 06:00:00 +0000 Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology TEL AVIV, Israel, June 2 /PRNewswire/ -- Clinical trial results using the regen(TM) system, the newest aesthetic solution powered by 3rd generation TriPollar RF technology on cellulite treatment and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3153 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3153 Tue, 02 Jun 2009 14:24:00 +0000 Movetis Releases New Data That Support Prucalopride's Favourable and Differentiated Efficacy and Cardiovascular Safety Profile CHICAGO, June 2 /PRNewswire/ -- Data from 7 prucalopride trials are being presented at the Digestive Disease Week (DDW) in Chicago. They confirm the consistent and predictable efficacy of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3150 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3150 Tue, 02 Jun 2009 11:35:00 +0000 Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus SUNNYVALE, California, June 1 /PRNewswire/ -- Clinical trial results presented at the Digestive Disease Week in Chicago today reveal that endoscopic radiofrequency ablation performed in a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3144 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3144 Mon, 01 Jun 2009 23:00:00 +0000 Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis NOVATO, California, June 1 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3143 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3143 Mon, 01 Jun 2009 17:30:00 +0000 Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors CAMBRIDGE, Massachusetts, June 1 /PRNewswire/ -- Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3140 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3140 Mon, 01 Jun 2009 15:17:00 +0000 Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients With Colorectal Cancer Liver Metastases who Have Exhausted Chemotherapy ORLANDO, Florida, June 1 /PRNewswire/ -- The time to progression of disease in patients with colorectal cancer liver metastases who have exhausted all chemotherapy options can be more than doubled... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3139 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3139 Mon, 01 Jun 2009 13:00:00 +0000 Heart Disease Treatment Breakthrough GATESHEAD, England, June 1 /PRNewswire/ -- A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3138 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3138 Mon, 01 Jun 2009 11:54:00 +0000 AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis LONDON, June 1 /PRNewswire/ -- Privately owned UK biotech company Daval International Limited (http://www.davalinternational.com) has been informed by Australia's Therapeutic Goods Administration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3137 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3137 Mon, 01 Jun 2009 10:56:00 +0000 PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer KVISTGAARD, Denmark, June 1 /PRNewswire/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3136 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3136 Mon, 01 Jun 2009 08:00:00 +0000 Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer MADRID, May 30 /PRNewswire/ -- The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3132 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3132 Sat, 30 May 2009 13:39:00 +0000 New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer COLLEGEVILLE, Pennsylvania, May 29 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3130 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3130 Fri, 29 May 2009 13:00:00 +0000 Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards HUNTINGTON BEACH, California, and AMSTERDAM, May 28 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3126 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3126 Thu, 28 May 2009 13:33:00 +0000 AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria AMSTERDAM, May 28 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3122 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3122 Thu, 28 May 2009 06:00:00 +0000 Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development SUNNYVALE, California, May 28 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3121 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3121 Thu, 28 May 2009 00:21:00 +0000 Invitation: PROSTVAC(TM) Wrap up KVISTGAARD, Denmark, May 27 /PRNewswire/ -- Following the presentation of data with PROSTVAC(TM) - a promising, late-stage vaccine candidate for the treatment of advanced prostate cancer, Bavarian... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3120 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3120 Wed, 27 May 2009 16:02:00 +0000 New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control LONDON, May 27 /PRNewswire/ -- Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3118 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3118 Wed, 27 May 2009 14:04:00 +0000 Bethesda-Based NHSi Wins US$2M Grant for Blood Technology BETHESDA, Maryland, May 26 /PRNewswire/ -- New Health Sciences Inc. (NHSi) has won a two-year award of US$1.9 million from the National Heart, Lung and Blood Institute of the National Institutes of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3109 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3109 Tue, 26 May 2009 15:11:00 +0000 Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models WELLESLEY HILLS, Massachusetts, May 26 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3108 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3108 Tue, 26 May 2009 14:00:00 +0000 Agendia Opens CLIA-Registered U.S. Genomics Laboratory HUNTINGTON BEACH, California and AMSTERDAM, May 26 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. clinical genomics laboratory in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3107 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3107 Tue, 26 May 2009 13:00:00 +0000 HRA Pharma Granted European Marketing Authorization for ellaOne(R) PARIS, May 26 /PRNewswire/ -- HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3106 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3106 Tue, 26 May 2009 12:12:00 +0000 ImmunoVaccine Technologies Partners With FIT Biotech to Advance a Therapeutic HIV Vaccine HALIFAX, Canada, May 26 /PRNewswire/ -- ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based , clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3100 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3100 Tue, 26 May 2009 06:00:00 +0000 InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Leon MD BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3096 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3096 Thu, 21 May 2009 13:44:00 +0000 Innovative Treatment Approach Offers New Hope for Eczema Sufferers With Moderate to Severe Disease PROTOPIC(R) PRAGUE, May 21 /PRNewswire/ -- Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3093 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3093 Thu, 21 May 2009 12:00:00 +0000 Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials INDIANAPOLIS, May 21 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3094 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3094 Thu, 21 May 2009 12:00:00 +0000 Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD LUTON, England, May 21 /PRNewswire/ -- Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease (COPD) show that... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3091 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3091 Thu, 21 May 2009 09:30:00 +0000 Phase III Data Show Novartis Investigational Bronchodilator QAB149 Significantly Improves Lung Function Over Current Treatments in COPD[1,2] BASEL, Switzerland, May 21 /PRNewswire/ -- **This press release is not intended for the UK media** http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3089 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3089 Thu, 21 May 2009 06:00:00 +0000 MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation BARCELONA, Spain, May 20 /PRNewswire/ -- Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3088 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3088 Wed, 20 May 2009 17:00:00 +0000 First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology LA JOLLA, California and KUALA LUMPUR, Malaysia, May 20 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company applying genomic-driven commercial solutions to address global issues,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3085 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3085 Wed, 20 May 2009 10:00:00 +0000 Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System ANN ARBOR, Michigan, May 20 /PRNewswire/ -- Terumo Heart Inc., a wholly owned subsidiary of Terumo Corporation, today announced reaching a critical milestone in the worldwide expansion of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3082 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3082 Wed, 20 May 2009 07:00:00 +0000 AMT Issues Business Update for First Quarter 2009 AMSTERDAM, May 19 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today issues it's business update for the first quarter of 2009,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3080 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3080 Tue, 19 May 2009 17:00:00 +0000 NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial BARCELONA, Spain, May 19 /PRNewswire/ -- At six months, the NEVO(TM) Sirolimus-eluting Coronary Stent, incorporating RES Technology(TM), was superior to the Taxus(R) Liberte(R) Stent in reducing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3079 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3079 Tue, 19 May 2009 14:54:00 +0000 Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data WARRENDALE, Pennsylvania, May 18 /PRNewswire/ -- MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3069 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3069 Mon, 18 May 2009 21:03:00 +0000 Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3060 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3060 Mon, 18 May 2009 07:30:00 +0000 Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies OXFORD, England, May 18 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3061 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3061 Mon, 18 May 2009 07:30:00 +0000 MS Society Calls on Brown to Ring-Fence Stem Cell Funds LONDON, May 18 /PRNewswire/ -- The MS Society has today (18 May) called on Gordon Brown to ring-fence funds for stem cell research into multiple sclerosis (MS). Four years ago the UK Government... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3057 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3057 Mon, 18 May 2009 00:01:00 +0000 Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor NERVIANO, Italy, May 13 /PRNewswire/ -- The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3043 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3043 Wed, 13 May 2009 08:00:00 +0000 Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain READING, England, May 8 /PRNewswire/ -- Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3026 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3026 Fri, 08 May 2009 14:51:00 +0000 Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain READING, England, May 8 /PRNewswire/ -- Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3024 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3024 Fri, 08 May 2009 07:00:00 +0000 Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery FRIMLEY, England, May 8 /PRNewswire/ -- Glivec(R) has been approved in the UK for the treatment of patients with the gastrointestinal cancer, KIT (CD117)-positive gastrointestinal stromal tumours... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3022 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3022 Fri, 08 May 2009 06:00:00 +0000 FDA Grants Priority Review Status to Prevnar 13 Marketing Application COLLEGEVILLE, Pennsylvania, May 7 /PRNewswire/ -- -- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- Wyeth Pharmaceuticals,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3017 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3017 Thu, 07 May 2009 13:00:00 +0000 Sirius Genomics Announces New Collaboration with Vanderbilt University VANCOUVER, May 7 /PRNewswire/ -- Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with Vanderbilt University to study... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3014 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3014 Thu, 07 May 2009 06:39:00 +0000 Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease GENEVA, Switzerland, May 7 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA (SWX: NWRN) announced today the initiation of the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3013 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3013 Thu, 07 May 2009 06:30:00 +0000 AMT Starts Preregistration Trial for Glybera(TM) AMSTERDAM, May 7 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the treatment of the first patient in a preregistration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3012 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3012 Thu, 07 May 2009 06:00:00 +0000 D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3010 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3010 Wed, 06 May 2009 13:00:00 +0000 Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3009 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3009 Wed, 06 May 2009 12:30:00 +0000 Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3007 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3007 Wed, 06 May 2009 11:22:00 +0000 InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients TEL AVIV, Israel, May 6 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the iMOS registry. MGuard(TM) was successfully implanted at... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3006 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3006 Wed, 06 May 2009 10:01:00 +0000 Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma EVRY, France, May 6 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3004 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/3004 Wed, 06 May 2009 07:00:00 +0000 Jubilant Enters Research Collaboration With AstraZeneca NOIDA, India, May 5 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2997 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2997 Tue, 05 May 2009 08:49:00 +0000 Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study NAPA, California, May 4 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2994 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2994 Mon, 04 May 2009 14:00:00 +0000 Are we Ignoring H2N3 at our Peril? LONDON, May 1 /PRNewswire/ -- Clinica is investigating the details and significance of Mexican health ministry statements that the H2N3 influenza virus was responsible for "the majority of cases... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2991 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2991 Fri, 01 May 2009 15:01:00 +0000 Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma LACHEN, Switzerland, May 1 /PRNewswire/ -- The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2989 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2989 Fri, 01 May 2009 12:40:00 +0000 Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip SUNNYVALE, California, April 30 /PRNewswire/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2978 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2978 Thu, 30 Apr 2009 13:00:00 +0000 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis SEATTLE and GENEVA, April 30 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2975 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2975 Thu, 30 Apr 2009 01:15:00 +0000 MS Society Statement on Oral Therapy Results LONDON, April 30 /PRNewswire/ -- Following the embargoed news released by the Queen Mary University of London concerning the oral MS drug cladribine and the results due to be presented at the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2974 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2974 Thu, 30 Apr 2009 00:01:00 +0000 Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications NOVATO, California, April 29 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced that the United States Patent and Trademark Office... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2967 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2967 Wed, 29 Apr 2009 11:30:00 +0000 Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) STOCKHOLM, Sweden, April 29 /PRNewswire/ -- Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2966 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2966 Wed, 29 Apr 2009 10:13:00 +0000 Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing SYDNEY, April 29 /PRNewswire/ -- Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2964 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2964 Wed, 29 Apr 2009 09:37:00 +0000 Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet ANTONY, France, April 29 /PRNewswire/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2963 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2963 Wed, 29 Apr 2009 08:38:00 +0000 Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009 KVISTGAARD, Denmark, April 28 /PRNewswire/ -- Yesterday Bavarian Nordic Announced its Interim Results for the First Quarter of 2009 - Positive Developments in the Biodefence and Cancer Business... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2959 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2959 Tue, 28 Apr 2009 12:19:00 +0000 AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe WOBURN, Massachusetts and VEDBAEK, Denmark, April 28 /PRNewswire/ -- AdvanDx today announced that it has launched a fast, 90 minutes protocol for all CE-IVD marked PNA FISH(R) tests in Europe. The... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2957 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2957 Tue, 28 Apr 2009 07:00:00 +0000 Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture COLLEGEVILLE, Pennsylvania, April 27 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has granted marketing authorization... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2953 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2953 Mon, 27 Apr 2009 14:00:00 +0000 Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin SUNNYVALE, California, April 27 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2951 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2951 Mon, 27 Apr 2009 12:00:00 +0000 An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients COLUMBIA, Maryland, April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediated immunity in immunosuppressed patient populations, numerous clinical investigations have... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2945 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2945 Fri, 24 Apr 2009 14:45:00 +0000 Society Responds to Guidance on Oral Salicylate Gels in Under-16s LONDON, April 23 /PRNewswire/ -- Parents and caregivers concerned about the use of Bonjela and Bonjela Cool Mint Gel on children under the age of 16 should consult their pharmacist, the Royal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2930 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2930 Wed, 22 Apr 2009 11:41:00 +0000 BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome NOVATO, California, April 21 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2924 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2924 Tue, 21 Apr 2009 21:00:00 +0000 NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device NESHER, Israel, April 21 /PRNewswire/ -- NanoVibronix, a medical device company specializing in applications that implement surface ultrasound waves, announced that its novel device has received CE... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2921 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2921 Tue, 21 Apr 2009 13:30:00 +0000 Newly Published Study Shows That Re-Treatment With Pegasys(R) (Peginterferon Alfa-2a) Provides Hepatitis C Patients With a Second Chance for a Cure BASEL, Switzerland, April 20 /PRNewswire/ -- New data published today in a major peer-reviewed journal, Annals of Internal Medicine, show that re-treatment with Pegasys(R) (peginterferon alfa-2a)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2914 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2914 Mon, 20 Apr 2009 22:00:00 +0000 Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2909 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2909 Mon, 20 Apr 2009 15:00:00 +0000 Psylin Neurosciences Commences Development of Compound for Depression SAN DIEGO, April 20 /PRNewswire/ -- Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today that it has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2907 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2907 Mon, 20 Apr 2009 13:00:00 +0000 Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting CAMBRIDGE, Massachusetts, April 19 /PRNewswire/ -- Mersana, a platform-based cancer therapeutics company, today announced positive results of preclinical studies for its second development... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2903 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2903 Sun, 19 Apr 2009 20:00:00 +0000 EAU Position Statement on Screening for Prostate Cancer ARNHEM, The Netherlands, April 16 /PRNewswire/ -- The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2891 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2891 Thu, 16 Apr 2009 12:07:00 +0000 Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries CLEVELAND, Ohio, April 16 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, today announced an agreement with Johnson & Johnson LLC for distribution of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2889 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2889 Thu, 16 Apr 2009 08:10:00 +0000 Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye EVRY, France, April 15 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2882 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2882 Wed, 15 Apr 2009 13:00:00 +0000 Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA UPPSALA, Sweden, April 14 /PRNewswire/ -- Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2879 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2879 Tue, 14 Apr 2009 11:19:00 +0000 Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer NOVATO, California, April 13 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced the appointment of Patrice P. Rioux, M.D., Ph.D., as... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2876 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2876 Mon, 13 Apr 2009 11:30:00 +0000 AACR Data Highlights InNexus Preclinical Antibody Candidate SCOTTSDALE, Arizona, April 9 /PRNewswire/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2870 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2870 Thu, 09 Apr 2009 14:00:00 +0000 Long-Term Tolerability and Safety Data of Abilify(R) in Combination Treatment for Patients With Bipolar I Disorder FLORENCE, Italy, April 9 /PRNewswire/ -- ABILIFY(R) (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2868 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2868 Thu, 09 Apr 2009 12:42:00 +0000 U-Systems, Inc. Selects Medidata Rave(R) for SOMO-INSIGHT Study of Automated Breast Ultrasound System NEW YORK, April 8 /PRNewswire/ -- Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that U-Systems, Inc. selected Medidata Rave(R) as its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2864 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2864 Wed, 08 Apr 2009 14:30:00 +0000 Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2863 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2863 Wed, 08 Apr 2009 13:46:00 +0000 World-First Launch of New Heart Drug LONDON, April 8 /PRNewswire/ -- UK patients are the first to benefit from the launch of a new heart drug prasugrel (Efient), following authorisation by the European Medicines Agency (EMEA). The... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2859 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2859 Wed, 08 Apr 2009 09:45:00 +0000 Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients ANN ARBOR, Michigan, April 7 /PRNewswire/ -- The DuraHeart(TM) Left Ventricular Assist System (LVAS) shows sustained benefits in providing safe and reliable long-term circulatory support with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2852 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2852 Tue, 07 Apr 2009 12:00:00 +0000 First Patients Enrolled in the Access-Europe Study of The MitraClip(R) Therapy MENLO PARK, California, April 6 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the first enrollment in the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2844 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2844 Mon, 06 Apr 2009 16:56:00 +0000 Orcrist Bio Inc. Receives Approval From European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 CALGARY, Canada, April 6 /PRNewswire/ -- Orcrist Bio Inc. (ORC) a biotechnology company developing stem cell-mobilizing pharmaceuticals, announced today the approval of its Phase I, open-label,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2843 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2843 Mon, 06 Apr 2009 13:00:00 +0000 NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology SAN JOSE, California, April 3 /PRNewswire/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2836 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2836 Fri, 03 Apr 2009 09:10:00 +0000 Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in Oncology Patients Receiving Highly Emetogenic Chemotherapy LUGANO, Switzerland, April 2 /PRNewswire/ -- A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2833 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2833 Thu, 02 Apr 2009 14:27:00 +0000 Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap VENLO, Netherlands, April 1 /PRNewswire/ -- Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonstrate that in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2824 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2824 Wed, 01 Apr 2009 22:00:00 +0000 Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray GENEVA, Switzerland, March 31 /PRNewswire/ -- Viroblock SA has announced today that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2814 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2814 Tue, 31 Mar 2009 15:00:00 +0000 BARC Central Laboratory Joins Alzheimer's Association Research Roundtable NEW YORK, March 30 /PRNewswire/ -- Biomarkers have become increasingly important to Alzheimer's disease research as a method for risk assessment, early detection, testing new therapies and eventual... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2806 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2806 Mon, 30 Mar 2009 19:31:00 +0000 Merck Serono: New Phase III Data for Cladribine Tablets to be Presented at the American Academy of Neurology 61st Annual Meeting in April 2009 GENEVA, Switzerland, March 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the American Academy of Neurology (AAN) has accepted a late-breaking... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2801 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2801 Mon, 30 Mar 2009 13:00:00 +0000 Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years ORLANDO, Florida, March 29 /PRNewswire/ -- Long-term data presented today from Abbott's (NYSE: ABT) SPIRIT II clinical trial demonstrated that the clinical advantages of the XIENCE V(R) Everolimus... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2799 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2799 Sun, 29 Mar 2009 14:30:00 +0000 MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up ORLANDO, Florida, March 28 /PRNewswire/ -- Percutaneous mitral valve repair using the MitraClip(R) system in symptomatic high-risk surgical patients with functional mitral regurgitation (FMR)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2798 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2798 Sat, 28 Mar 2009 19:00:00 +0000 Edoxaban - Factor Xa Inhibitor Enters Phase III With Optimal Dose MUNICH, March 27 /PRNewswire/ -- Edoxaban (DU-176b) is a direct Factor Xa inhibitor and is developed to prevent thromboembolic events such as stroke and pulmonary embolism. The Phase II Edoxaban... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2793 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2793 Fri, 27 Mar 2009 11:21:00 +0000 Bariatric Surgery as a Cure for Diabetes: Can we Stomach it? LONDON, March 24 /PRNewswire/ -- For the first time ever, experts in bariatric surgery gave a lecture on how weight loss surgery for morbidly obese patients can cure type 2 diabetes, at the Diabetes... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2763 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2763 Tue, 24 Mar 2009 13:55:00 +0000 Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial ABBOTT PARK, Illinois, March 24 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2762 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2762 Tue, 24 Mar 2009 12:30:00 +0000 Vantia Therapeutics' Pipeline Continues to Mature SOUTHAMPTON, England, March 24 /PRNewswire/ -- Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2759 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2759 Tue, 24 Mar 2009 11:02:00 +0000 With New National Immunisation Programme in Saudi Arabia, Thirty-Five Countries Now Offer Routine Immunisation Against Pneumococcal Disease With Prevenar MAIDENHEAD, England, March 23 /PRNewswire/ -- Wyeth today announced that Prevenar(TM) (Pneumococcal saccharide conjugated vaccine, Adsorbed) has been added to Saudi Arabia's national childhood... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2745 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2745 Mon, 23 Mar 2009 06:00:00 +0000 Another LNA-based RNA Inhibitor Enters Clinical Trials COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2742 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2742 Fri, 20 Mar 2009 12:05:00 +0000 Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2740 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2740 Fri, 20 Mar 2009 11:00:00 +0000 The French Institute I-Stem Realizes First Innovative Screens Using Stem Cells to Identify Drugs for Myotonic Dystrophy, DM1 Disease EVRY, France, March 19 /PRNewswire/ -- Four research teams of I-STEM[*] have joined forces in a collaborative project that has just achieved a first pilot therapy-oriented screen of compounds and RNA... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2735 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2735 Thu, 19 Mar 2009 08:00:00 +0000 PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer Study STOCKHOLM, Sweden, March 18 /PRNewswire/ -- Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2728 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2728 Wed, 18 Mar 2009 16:00:00 +0000 U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent HOUSTON, March 18 /PRNewswire/ -- IDEV Technologies Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive technologies, announced today that the U.S. Food and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2725 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2725 Wed, 18 Mar 2009 13:00:00 +0000 Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System) DUBLIN, March 16 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2712 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2712 Mon, 16 Mar 2009 12:34:00 +0000 WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer NAPA, California, March 13 /PRNewswire/ -- On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University of Maryland School of Medicine, was featured on WBAL-AM 1090 in a segment... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2709 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2709 Fri, 13 Mar 2009 13:25:00 +0000 The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent ABBOTT PARK, Illinois, March 12 /PRNewswire/ -- A comprehensive analysis published today in The Lancet, one of the world's leading medical journals, from the ABSORB clinical trial demonstrated that... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2707 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2707 Thu, 12 Mar 2009 22:30:00 +0000 BioCis Pharma Starts Phase IIa Trial in Psoriasis TURKU, Finland, March 12 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2704 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2704 Thu, 12 Mar 2009 14:00:00 +0000 Simbionix Increases Product Offerings for OB/GYN Physicians CLEVELAND and ZURICH, Switzerland, March 11 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, and VirtaMed, a Swiss medical engineering company, announced today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2698 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2698 Wed, 11 Mar 2009 10:33:00 +0000 Shire Announces Launch of FOSRENOL(R) in Japan DUBLIN, March 11 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the Japanese launch of FOSRENOL(R) (lanthanum carbonate), which... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2696 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2696 Wed, 11 Mar 2009 08:00:00 +0000 Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of Disease EINDHOVEN, The Netherlands, March 10 /PRNewswire/ -- The Center for Translational Molecular Medicine (CTMM) - the Dutch public-private partnership committed to the research and development of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2692 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2692 Tue, 10 Mar 2009 16:22:00 +0000 First Swiss Patients Treated with the Percutaneous MitraClip(R) System MENLO PARK, California, March 10 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first series of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2691 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2691 Tue, 10 Mar 2009 14:30:00 +0000 Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe CAMBRIDGE, Massachusetts, March 10 /PRNewswire/ -- Tolerx, Inc., today announced that DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), the Phase 3 trial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2685 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2685 Tue, 10 Mar 2009 08:00:00 +0000 ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) LEUVEN, Belgium, March 6 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2674 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2674 Fri, 06 Mar 2009 06:30:00 +0000 NICE Recommends Xarelto(R) (Rivaroxaban) Use in NHS LONDON, March 5 /PRNewswire/ -- The National Institute for Health and Clinical Excellence (NICE) has issued an initial positive opinion on the new oral anticoagulant Xarelto(R) for the prevention... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2670 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2670 Thu, 05 Mar 2009 12:33:00 +0000 Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved STOCKHOLM, March 4 /PRNewswire/ -- Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd(R) diabetes vaccine in children with high risk to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2664 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2664 Wed, 04 Mar 2009 15:12:00 +0000 FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product BRITISH COLUMBIA, Canada, March 3 /PRNewswire/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2661 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2661 Tue, 03 Mar 2009 21:46:00 +0000 Drug Development Program Started Based on CAP(R) Human Cell Line COLOGNE, Germany, March 3 /PRNewswire/ -- Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2659 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2659 Tue, 03 Mar 2009 15:35:00 +0000 Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM) NEW YORK, March 3 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2657 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2657 Tue, 03 Mar 2009 10:50:00 +0000 Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting KVISTGAARD, Denmark, March 3 /PRNewswire/ -- Following the completion of the Phase II clinical development of IMVAMUNE(R), a third-generation smallpox vaccine, Bavarian Nordic has held an end of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2655 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2655 Tue, 03 Mar 2009 10:34:00 +0000 Gene Therapy: G EVRY, France, March 3 /PRNewswire/ -- Genethon, the french laboratory created and funded by the AFM (French Association against Myopathies) using donations from T http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2653 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2653 Tue, 03 Mar 2009 08:00:00 +0000 Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2652 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2652 Tue, 03 Mar 2009 07:30:00 +0000 Endo Licenses Novel Pain Therapy From Grunenthal AACHEN, Germany, March 2 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced that it has licensed from Grunenthal the exclusive rights to develop and market the investigational drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2648 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2648 Mon, 02 Mar 2009 17:40:00 +0000 Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2631 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2631 Fri, 27 Feb 2009 07:00:00 +0000 Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects READING, England, February 26 /PRNewswire/ -- Archimedes Pharma Limited, the pan-European specialty pharmaceutical company, today announces positive headline data from its recently completed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2626 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2626 Thu, 26 Feb 2009 10:02:00 +0000 Scientific Recognition for Solianis Based on Successful Tests ZURICH, Switzerland, February 26 /PRNewswire/ -- Recently, Solianis successfully finalized a series of tests during which patients with diabetes have worn its multisensor device for non-invasive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2623 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2623 Thu, 26 Feb 2009 09:46:00 +0000 Flawed Science in Last-Minute Southampton Fluoridation Reports NEW YORK, February 26 /PRNewswire/ -- The South Central Strategic Health Authority (SHA) hired Bazian Ltd. to review fluoride safety concerns raised by a 2006 report of the US National Research... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2622 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2622 Thu, 26 Feb 2009 06:35:00 +0000 Bavarian Nordic Reports Further Data on PROSTVAC(TM) KVISTGAARD, Denmark, February 25 /PRNewswire/ -- Bavarian Nordic today announced that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2613 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2613 Wed, 25 Feb 2009 10:59:00 +0000 Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance GENEVA, February 24 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and Ambrx Inc, today announced a global strategic collaboration to develop and commercialize Ambrx's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2605 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2605 Tue, 24 Feb 2009 14:00:00 +0000 Bavarian Nordic Updates on Phase I/II Studies With Breast Cancer Vaccine KVISTGARD, Denmark, February 23 /PRNewswire/ -- Bavarian Nordic today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2594 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2594 Mon, 23 Feb 2009 09:36:00 +0000 Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009 CARLSBAD, California, February 20 /PRNewswire/ -- In a clinical trial sponsored by PhotoThera, Inc., transcranial laser therapy (TLT) for acute ischemic stroke within 24 hours of stroke... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2591 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2591 Fri, 20 Feb 2009 21:00:00 +0000 European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R) GENEVA, Switzerland, February 19 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Medicines Agency (EMEA) has recommended to the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2581 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2581 Thu, 19 Feb 2009 17:49:00 +0000 European Commisssion Grants Ferring Pharmaceuticals Approval of FIRMAGON(R) (Degarelix) for Treatment of Prostate Cancer SAINT-PREX, Switzerland, February 19 /PRNewswire/ -- Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON(R) (degarelix), a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2580 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2580 Thu, 19 Feb 2009 15:47:00 +0000 Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study LYON, France, February 18 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetravalent dengue... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2568 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2568 Wed, 18 Feb 2009 08:00:00 +0000 Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile LYON, France, February 17 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN et NYSE : SNY), announced today that it is sponsoring a phase II clinical study... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2558 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2558 Tue, 17 Feb 2009 08:00:00 +0000 Tramacet(R) Builds Gr LONDON, February 16 /PRNewswire/ -- From 1st January Gr http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2556 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2556 Mon, 16 Feb 2009 12:02:00 +0000 Coartem(R) Dispersible, the First Dispersible ACT* for Children, Launched This Week in Africa by Novartis and Medicines for Malaria Venture DAR ES SALAAM, Tanzania, February 16 /PRNewswire/ -- Novartis and Medicines for Malaria Venture (MMV) announced today the African launch of Coartem(R) Dispersible. Coartem(R) Dispersible is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2554 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2554 Mon, 16 Feb 2009 05:00:00 +0000 Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation COLUMBIA, Maryland and BILLERICA, Massachusetts, February 12 /PRNewswire/ -- Nucletron, a knowledge-based leader in radiation oncology, and Advanced Radiation Therapy (ART) announced today an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2551 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2551 Thu, 12 Feb 2009 18:10:00 +0000 New Method Protects Anacidic Stomachs From Carcinogenic Acetaldehyde HELSINKI, February 12 /PRNewswire/ -- Researchers at the University of Helsinki and the Helsinki University Central Hospital have in cooperation with Biohit Oyj developed a new method that helps... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2549 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2549 Thu, 12 Feb 2009 15:00:00 +0000 Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium NAPA, California, February 12 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2547 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2547 Thu, 12 Feb 2009 14:25:00 +0000 New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation PARIS, February 12 /PRNewswire/ -- Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2545 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2545 Thu, 12 Feb 2009 11:09:00 +0000 CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved in the European Union for Treatment of Patients With Diabetes WARREN, New Jersey, February 11 /PRNewswire/ -- The CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent has received CE marking within the European Union (EU) for treatment of patients... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2542 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2542 Wed, 11 Feb 2009 17:02:00 +0000 FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers NERVIANO, Italy, February 10 /PRNewswire/ -- Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2533 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2533 Tue, 10 Feb 2009 08:00:00 +0000 Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 9 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), announces that it has received Paragraph IV Notice letters from Barr Laboratories, Inc.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2531 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2531 Mon, 09 Feb 2009 12:00:00 +0000 Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions LAUSANNE, Switzerland, and PARIS, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2528 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2528 Mon, 09 Feb 2009 09:00:00 +0000 Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) ZUG, Switzerland, February 6 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2525 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2525 Fri, 06 Feb 2009 23:38:00 +0000 Genetic Study Shows Direct Link Between Vitamin D and Ms Susceptibility 'Gene' LONDON, February 5 /PRNewswire/ -- Scientists have found evidence that a direct interaction between vitamin D and a common genetic variant alters the risk of developing multiple sclerosis (MS). ... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2524 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2524 Thu, 05 Feb 2009 22:00:00 +0000 Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) NOVATO, California, February 5 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2521 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2521 Thu, 05 Feb 2009 11:30:00 +0000 Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2519 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2519 Wed, 04 Feb 2009 14:36:00 +0000 Cambridge Cognition Welcomes the Launch of the First National Dementia Strategy CAMBRIDGE, England, February 3 /PRNewswire/ -- Cambridge Cognition Ltd, developers of a clinical diagnostic product that provides early warning of neurodegenerative conditions including Alzheimer's,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2514 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2514 Tue, 03 Feb 2009 12:40:00 +0000 Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2512 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2512 Tue, 03 Feb 2009 09:00:00 +0000 Algeta to Enroll US Patients Into Global Phase III ALSYMPCA Trial Following Successful End-of-Phase II Meeting With FDA OSLO, Norway, February 3 /PRNewswire/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it is to enroll US patients into its ALSYMPCA phase III trial evaluating Alpharadin... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2513 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2513 Tue, 03 Feb 2009 09:00:00 +0000 Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial GENEVA, Switzerland, February 3 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA (SWX: NWRN) announced today that the first Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2510 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2510 Tue, 03 Feb 2009 06:00:00 +0000 BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device LAVAL, Quebec, February 2 /PRNewswire/ -- BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has completed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2509 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2509 Mon, 02 Feb 2009 16:06:00 +0000 Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems LEUVEN, Belgium, February 2 /PRNewswire/ -- A 74-year-old prostate cancer patient has become the first person in Belgium to be treated using a new, faster form of radiotherapy that extends more... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2508 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2508 Mon, 02 Feb 2009 13:00:00 +0000 Foreign Medical Devices are in High Demand in Russia LAHTI, Finland, February 2 /PRNewswire/ -- The demand for medical devices has been increasing in recent years in Russia. Demand for imported high-tech medical devices is so high because local... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2506 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2506 Mon, 02 Feb 2009 11:48:00 +0000 ECASS 3 Study Receives Recognition From the European Stroke Organisation and The Lancet INGELHEIM, Germany, January 30 /PRNewswire/ -- Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2498 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2498 Fri, 30 Jan 2009 08:30:00 +0000 Stem Cell Transplant Trial Results - The Lancet LONDON, January 30 /PRNewswire/ -- Ahead of the publication on Friday 30 January of a paper in The Lancet Neurology reporting the results of a trial involving stem cell transplantation in people with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2496 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2496 Thu, 29 Jan 2009 15:16:00 +0000 AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly AMSTERDAM, The Netherlands, January 28 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today during the Phacilitate Cell &... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2490 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2490 Wed, 28 Jan 2009 18:30:00 +0000 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases DAVOS, Switzerland, January 28 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, and mondoBIOTECH AG, a Swiss research company dedicated to the development of treatments... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2485 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2485 Wed, 28 Jan 2009 07:58:00 +0000 Senetek PLC Launches Dedicated Pyratine-6(TM) Website NAPA, California, January 27 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2478 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2478 Tue, 27 Jan 2009 14:00:00 +0000 Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass MALVERN, Pennsylvania, January 26 /PRNewswire/ -- A pivotal clinical trial published in the January 2009 issue of the journal Gynecologic Oncology demonstrated the utility of combining... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2473 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2473 Mon, 26 Jan 2009 15:12:00 +0000 ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication DUBLIN, Ireland, January 26 /PRNewswire/ -- ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2467 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2467 Mon, 26 Jan 2009 10:56:00 +0000 ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF) LEUVEN, Belgium and LUND, Sweden, January 26 /PRNewswire/ -- ThromboGenics NV (EURONEXT:THR) and BioInvent International AB (OMXS:BINV) announce today that they have received a technology... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2465 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2465 Mon, 26 Jan 2009 07:00:00 +0000 Targin(R) (Oral Oxycodone/Naloxone Prolonged-Release Tablet) now Launching Across Europe to Control Severe Chronic Pain With Significantly Reduced Risk of Opioid-Induced Constipation CAMBRIDGE, England, January 26 /PRNewswire/ -- Mundipharma today announced that 13 countries* to date have received approval of Targin, a new combination therapy designed to control severe chronic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2464 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2464 Mon, 26 Jan 2009 00:01:00 +0000 Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial GENEVA, Switzerland, January 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the CLARITY(1) Phase III pivotal trial of its proprietary oral... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2459 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2459 Fri, 23 Jan 2009 07:00:00 +0000 Blood Pressure Goal Missed by Two Thirds of Patients MUNICH, Germany, January 22 /PRNewswire/ -- Less than a third of patients in Europe achieve acceptable blood pressure control. The remaining two thirds are "challenging patients" i.e. patients whose... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2455 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2455 Thu, 22 Jan 2009 11:00:00 +0000 Phidea Srl and Marvin Research Srl Announce Completion of Merger MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2450 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2450 Thu, 22 Jan 2009 07:00:00 +0000 STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany ANTONY, France, January 19 /PRNewswire/ -- Stallergenes S.A. today announced that the Paul Ehrlich Institute, the German agency in charge of regulating biological products, has approved its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2436 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2436 Mon, 19 Jan 2009 22:48:00 +0000 UK Must Maintain its Momentum in Stem Cell Expertise LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2435 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2435 Mon, 19 Jan 2009 13:25:00 +0000 Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding MONT-SAINT-GUIBERT, Belgium, January 19 /PRNewswire/ -- Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2432 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2432 Mon, 19 Jan 2009 10:13:00 +0000 Malaria: New Treatment is Upcoming ROME, January 16 /PRNewswire/ -- The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2424 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2424 Fri, 16 Jan 2009 07:00:00 +0000 Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline) TOKYO, January 15 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Chiyoda-ku, Tokyo Japan; President, Dr. Yuzuru Matsuda) announced on January 15 (Tokyo Time) that it has decided to continue the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2416 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2416 Thu, 15 Jan 2009 02:00:00 +0000 Do Children Prefer Fruit to Fizzies? You'll be Surprised LONDON, January 14 /PRNewswire/ -- Yes, it's true - UK children really do prefer the taste of oranges and strawberries over soft-drink flavours like fizzy cola. That's just one of the findings... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2412 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2412 Wed, 14 Jan 2009 15:32:00 +0000 BioSyntech to Conclude Enrolment for Pivotal BST-CarGel(R) Trial in February 2009 LAVAL, Quebec, January 14 /PRNewswire/ -- BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2411 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2411 Wed, 14 Jan 2009 15:00:00 +0000 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer OSLO, Norway, January 14 /PRNewswire/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today it has completed its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2404 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2404 Wed, 14 Jan 2009 10:00:00 +0000 Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect WASHINGTON, January 13 /PRNewswire/ -- The Association of Clinical Research Organizations (ACRO), which represents the clinical outsourcing industry to regulators, biopharmaceutical clients, policy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2402 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2402 Tue, 13 Jan 2009 14:35:00 +0000 InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA BRITISH COLUMBIA, Canada, January 13 /PRNewswire/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2401 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2401 Tue, 13 Jan 2009 14:25:00 +0000 The Turkish Government Adds Wyeth's 7-valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedule MAIDENHEAD, England, January 13 /PRNewswire/ -- Turkey has initiated a national immunization programme (NIP) against pneumococcal disease with Wyeth's Prevenar(TM) (Pneumococcal saccharide conjugated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2397 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2397 Tue, 13 Jan 2009 09:53:00 +0000 Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2395 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2395 Tue, 13 Jan 2009 08:00:00 +0000 ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2394 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2394 Tue, 13 Jan 2009 07:00:00 +0000 Large-Scale Testing Initiated in France With 10,000 Blood Samples Tested for vCJD TORONTO, Canada, January 13 /PRNewswire/ -- Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced it has tested 10,000 blood donations... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2392 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2392 Tue, 13 Jan 2009 05:02:00 +0000 Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia CAMBRIDGE, Massachusetts, January 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2386 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2386 Mon, 12 Jan 2009 11:00:00 +0000 Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology Limited, a privately-held biotechnology company, announces a significant Collaboration and License Agreement with GlaxoSmithKline to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2382 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2382 Mon, 12 Jan 2009 07:00:00 +0000 ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity ZURICH, Switzerland, January 9 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2380 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2380 Fri, 09 Jan 2009 09:00:00 +0000 ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease LEUVEN, Belgium, January 9 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, announces... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2377 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2377 Fri, 09 Jan 2009 06:00:00 +0000 Treatment Approval - a Step Forward in Managing Severe Psoriasis in Children TAPLOW, England, January 8 /PRNewswire/ -- Wyeth Pharmaceuticals has today announced that Enbrel(R) (etanercept) is approved for the treatment of chronic severe plaque psoriasis in children aged 8... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2373 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2373 Thu, 08 Jan 2009 13:30:00 +0000 Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project BOZEN, Italy, January 5 /PRNewswire/ -- Health Robotics today announced that the European Union (EU) Commission and eTen have made available the first results of the SafeChemo Project it sponsored at... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2354 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2354 Mon, 05 Jan 2009 14:00:00 +0000 Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice GRONINGEN, The Netherlands, December 31 /PRNewswire/ -- Results from a landmark trial published today in the New England Journal of Medicine, show that in transplanted kidneys preserved... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2352 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2352 Wed, 31 Dec 2008 22:00:00 +0000 Serbia First in Europe to Participate in Phase 3 Clinical Trial of Lung Cancer Vaccine BELGRADE, Serbia, December 29 /PRNewswire/ -- NovaRx Corporation today announced the opening of the company's pivotal Phase 3 clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2346 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2346 Mon, 29 Dec 2008 07:00:00 +0000 FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer PARSIPPANY, New Jersey, December 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2345 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2345 Wed, 24 Dec 2008 23:30:00 +0000 Rosetta Genomics Announces Commercial Availability of Its Second MicroRNA-Based Diagnostic Test - miRview(TM) mets; Will Hold Teleconference Today to Discuss Launch of Products REHOVOT, Israel; JERSEY CITY, New Jersey; PHILADELPHIA, December 22 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2341 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2341 Mon, 22 Dec 2008 13:00:00 +0000 Glenmark Expects Launch of Crofelemer in ROW Countries (Developing Economies) by 2010 - Potential First-in-Class for HIV-Associated Diarrhea: Molecule Currently in Phase 3 Trials, Granted Fast Track Designation by US-FDA MUMBAI, December 22 /PRNewswire/ -- Glenmark Pharmaceuticals Limited today announced new developments that should accelerate the launch of Crofelemer, a novel drug in development for multiple... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2340 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2340 Mon, 22 Dec 2008 12:27:00 +0000 Blood Test for vCJD Achieves 100% Accuracy TORONTO, December 19 /PRNewswire/ -- Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced it achieved 100% sensitivity and 100%... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2337 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2337 Fri, 19 Dec 2008 13:15:00 +0000 Neuralstem Files FDA Application for First ALS Stem Cell Trial ROCKVILLE, Maryland, December 19 /PRNewswire/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced this morning that it has filed an Investigational New Drug (IND) application with the U.S.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2333 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2333 Fri, 19 Dec 2008 07:00:00 +0000 Committee for Medicinal Products for Human Use (CHMP) Recommends Granting Marketing Authorisation for FIRMAGON(R) (degarelix) for Treatment of Prostate Cancer SAINT PREX, Switzerland, December 18 /PRNewswire/ -- Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2329 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2329 Thu, 18 Dec 2008 18:44:00 +0000 Phase III Study Data on Movetis' Resolor(R) (prucalopride) for Patients With Chronic Constipation Published in Gut and Alimentary Pharmacology and Therapeutics TURNHOUT, Belgium, December 18 /PRNewswire/ -- The Gut and Alimentary Pharmacology and Therapeutics (APT) articles, together with the first paper on the pivotal Phase III data in the New England... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2325 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2325 Thu, 18 Dec 2008 14:11:00 +0000 EpiDerm's Skin Irritation Test Fully Validated in European Union ASHLAND, Massachusetts, December 17 /PRNewswire/ -- MatTek Corporation today announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the scientific validity of the Modified... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2322 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2322 Wed, 17 Dec 2008 19:59:00 +0000 Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test MALVERN, Pennsylvania and BASEL, Switzerland, December 16 /PRNewswire/ -- Fujirebio Diagnostics, Inc. and Roche Diagnostics announced today a worldwide license and supply agreement for the HE4... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2315 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2315 Tue, 16 Dec 2008 15:39:00 +0000 Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ -- Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2298 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2298 Sat, 13 Dec 2008 15:32:00 +0000 Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer HUNTINGTON BEACH, California and AMSTERDAM, December 12 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2296 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2296 Fri, 12 Dec 2008 14:38:00 +0000 Merck Serono's Kuvan(R) Receives Marketing Authorization in Europe GENEVA, Switzerland, December 9 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2279 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2279 Tue, 09 Dec 2008 11:23:00 +0000 VELCADE(R) (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations BEERSE, Belgium, December 9 /PRNewswire/ -- Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2278 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2278 Tue, 09 Dec 2008 08:00:00 +0000 Data Shows Longest Ever Survival for Patients With Life-Threatening Leukaemia Treated With Breakthrough Treatment FRIMLEY, England, December 8 /PRNewswire/ -- Nearly nine out of ten patients (86 percent) with a life-threatening leukaemia are still alive seven years after diagnosis when treated with Glivec... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2276 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2276 Mon, 08 Dec 2008 22:00:00 +0000 Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2275 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2275 Mon, 08 Dec 2008 16:50:00 +0000 Non-Invasive Glucose Monitoring - Solianis Monitoring AG ZURICH, Switzerland, December 8 /PRNewswire/ -- Solianis has just finalised a test series in which patients with diabetes have worn the first configuration of the multisensor system for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2274 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2274 Mon, 08 Dec 2008 15:01:00 +0000 Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) PORTO, Portugal, December 8 /PRNewswire/ -- Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2273 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2273 Mon, 08 Dec 2008 15:00:00 +0000 Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2271 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2271 Mon, 08 Dec 2008 13:46:00 +0000 MGuard(TM) Coronary Stent System Approved in Israel TEL AVIV, Israel, December 8 /PRNewswire/ -- InspireMD, Ltd. announced that the MGuard(TM) coronary stent system has been approved for use in Israel by the Israeli Ministry of Health. The... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2268 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2268 Mon, 08 Dec 2008 09:00:00 +0000 First Head-To-Head Study Shows That Protelos(R) (Strontium Ranelate) Builds Better Bone Than Bisphosphonate PARIS, December 8 /PRNewswire/ -- The osteoporosis treatment Protelos(R) (strontium ranelate) significantly improved bone structure in postmenopausal women when compared to the bisphosphonate... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2265 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2265 Mon, 08 Dec 2008 08:00:00 +0000 Cambridge Laboratories Announces Approval of Tetrabenazine in Spain DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ -- Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2263 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2263 Mon, 08 Dec 2008 07:00:00 +0000 DAIICHI SANKYO Initiates Phase III Trial of its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation TOKYO, MUNICH, Germany and EDISON, New Jersey, December 7 /PRNewswire/ -- DAIICHI SANKYO Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trials for DU-176b,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2261 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2261 Sun, 07 Dec 2008 17:30:00 +0000 New Phase II Data Provide Insight Into Optimal Dosing of Oral Factor Xa Inhibitor, DU-176b in Patients With Non-Valvular Atrial Fibrillation SAN FRANCISCO, December 7 /PRNewswire/ -- Patients with non-valvular atrial fibrillation receiving either 60 mg or 30 mg once per day of DU-176b, an investigational oral factor Xa inhibitor,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2262 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2262 Sun, 07 Dec 2008 17:30:00 +0000 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System MENLO PARK, California, December 4 /PRNewswire/ -- Long-term data published in EuroIntervention showed that the expected decrease in Mitral Vale Area (MVA) after repair with the MitraClip(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2256 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2256 Thu, 04 Dec 2008 19:07:00 +0000 Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2254 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2254 Thu, 04 Dec 2008 15:07:00 +0000 European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure BASEL, Switzerland, December 4 /PRNewswire/ -- Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (40 KD)) plus Copegus(R) (ribavirin) for the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2253 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2253 Thu, 04 Dec 2008 14:40:00 +0000 Results From the First and Largest Collaborative Study Confirm Role of Enbrel(R) in Psoriatic Arthritis MAIDENHEAD, England, December 4 /PRNewswire/ -- New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce Enbrel's ability... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2250 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2250 Thu, 04 Dec 2008 10:00:00 +0000 European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure BASEL, December 4 /PRNewswire/ -- Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (0 KD)) plus Copegus(R) (ribavirin) for the retreatment of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2247 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2247 Thu, 04 Dec 2008 06:30:00 +0000 ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials MONTR http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2246 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2246 Wed, 03 Dec 2008 22:52:00 +0000 Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children COLLEGEVILLE, Pennsylvania, December 3 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing authorization application (MAA) to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2242 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2242 Wed, 03 Dec 2008 14:15:00 +0000 Detection of All 24 Known Bluetongue Virus Serotypes: Prionics Launches a Highly Effective Test for the Early Detection of Bluetongue Virus (BTV) ZURICH, Switzerland, December 3 /PRNewswire/ -- Prionics, a world leader in farm animal diagnostics, has launched a highly effective and reliable ELISA for the early detection of antibodies specific... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2241 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2241 Wed, 03 Dec 2008 13:44:00 +0000 The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness KVISTGARD, Denmark, December 1 /PRNewswire/ -- Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2218 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2218 Mon, 01 Dec 2008 08:00:00 +0000 Cambridge Laboratories Announces Launch of XENAZINE(R) (Tetrabenazine) in the US NEWCASTLE, England, December 1 /PRNewswire/ -- Cambridge Laboratories Group Limited ("Cambridge"), the privately-owned specialty pharmaceutical company, today announces that XENAZINE(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2217 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2217 Mon, 01 Dec 2008 07:00:00 +0000 eTIPs - electronic-Targeted Intervention for Psoriasis ST ALBANS, England, November 28 /PRNewswire/ -- Psoriasis affects 2-3% of people in the UK and can create both physical and psychological distress. Psychological discomfort is made worse by the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2213 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2213 Fri, 28 Nov 2008 10:36:00 +0000 German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 G http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2212 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2212 Fri, 28 Nov 2008 08:30:00 +0000 Valdoxan(R), the First Melatonergic Antidepressant, Receives EU CHMP Positive Opinion for Major Depressive Disorder PARIS, November 21 /PRNewswire/ -- The first melatonergic antidepressant - Valdoxan(R)/Thymanax(R) (agomelatine) - has received a positive opinion from the European Medicines Agency's (EMEA)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2186 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2186 Fri, 21 Nov 2008 16:09:00 +0000 Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union THOUSAND OAKS, California, November 21 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2185 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2185 Fri, 21 Nov 2008 14:25:00 +0000 New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority for the Treatment of Moderate to Severe Plaque Psoriasis BEERSE, Belgium, November 21 /PRNewswire/ -- Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2187 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2187 Fri, 21 Nov 2008 11:51:00 +0000 Philips and Concateno Announce Revolutionary Drugs-of-Abuse Testing System LONDON and AMSTERDAM, November 20 /PRNewswire/ -- Concateno plc, Europe's largest provider of drug and alcohol testing programmes, and Royal Philips Electronics (NYSE:PHG, AEX:PHI) have today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2176 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2176 Thu, 20 Nov 2008 14:54:00 +0000 Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 CORK, Ireland, November 20 /PRNewswire/ -- New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2169 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2169 Thu, 20 Nov 2008 08:30:00 +0000 Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment CORK, Ireland, November 20 /PRNewswire/ -- Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2170 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2170 Thu, 20 Nov 2008 08:30:00 +0000 Switching to Once-Monthly Mircera Could Lead to Major Time Savings and Help Simplify Anaemia Management BASEL, Switzerland, November 20 /PRNewswire/ -- Switching dialysis patients to once-monthly Mircera(R) from older, more frequently dosed erythropoiesis stimulating agents (ESAs) could reduce... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2166 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2166 Thu, 20 Nov 2008 06:30:00 +0000 IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP) IRVINE, California, November 18 /PRNewswire/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2152 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2152 Tue, 18 Nov 2008 12:30:00 +0000 Covered Stent Use Minimized by European Health Care Reforms, According to Millennium Research Group WALTHAM, Massachusetts, November 17 /PRNewswire/ -- According to Millennium Research Group's (MRG's) Europe II Markets for Peripheral Vascular Devices report, covering Spain, Switzerland, Benelux,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2140 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2140 Mon, 17 Nov 2008 08:07:00 +0000 First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120) INGELHEIM, Germany, November 17 /PRNewswire/ -- Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2137 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2137 Mon, 17 Nov 2008 07:00:00 +0000 New Data, New Directions in the Management of Mood and Anxiety Disorders VIENNA, Austria, November 14 /PRNewswire/ -- Clinicians and researchers from around the world attended this week's 8th International Forum on Mood and Anxiety disorders in Vienna, Austria to discuss... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2132 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2132 Fri, 14 Nov 2008 14:31:00 +0000 ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders LEUVEN, Belgium, November 14 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, announces promising six month... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2129 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2129 Fri, 14 Nov 2008 06:00:00 +0000 Scientific Presentation During "Medica" on November 21st , 2008 - Invitation MUNICH and DUSSELDORF, Germany, November 13 /PRNewswire/ -- While the influence of the flow of energy on human persistence and well-being has been a known fact in Asia for many centuries, the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2122 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2122 Thu, 13 Nov 2008 08:00:00 +0000 DAIICHI SANKYO EUROPE GmbH Announce SEVIKAR(R), a New Fixed Dose Combination Treatment for Essential Hypertension MUNICH, Germany, November 12 /PRNewswire/ -- DAIICHI SANKYO EUROPE GmbH announces today that they received marketing approval for SEVIKAR(R), a new fixed dose combination treatment for essential... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2116 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2116 Wed, 12 Nov 2008 16:00:00 +0000 Vascular Surgeons Agree: Case Rehearsal Improves Outcomes CLEVELAND, Ohio and LOD, Israel, November 12 /PRNewswire/ -- Surgeons at the University of Rochester Medical Center, NY indicated that patient-specific CTA data can be converted to an endovascular... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2114 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2114 Wed, 12 Nov 2008 14:57:00 +0000 Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2108 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2108 Wed, 12 Nov 2008 08:30:00 +0000 Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program NOVATO, California, November 11 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced positive results in its Phase IIa study of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2104 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2104 Tue, 11 Nov 2008 15:00:00 +0000 PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF MONTEREY, California, November 10 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2093 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2093 Mon, 10 Nov 2008 19:15:00 +0000 RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease CALGARY, Canada, November 10 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2092 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2092 Mon, 10 Nov 2008 17:15:00 +0000 Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH COPENHAGEN, November 10 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2091 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2091 Mon, 10 Nov 2008 16:16:00 +0000 Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial ATLANTA, November 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2090 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2090 Mon, 10 Nov 2008 16:07:00 +0000 Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection LAUSANNE, Switzerland, November 10 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2088 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2088 Mon, 10 Nov 2008 14:22:00 +0000 Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc. CAMBRIDGE, England, November 10 /PRNewswire/ -- Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that it has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2086 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2086 Mon, 10 Nov 2008 13:47:00 +0000 Survey Results Indicate Focus on Earlier Treatment Will Help to Address the Growing Medical and Economic Burden of Type 2 Diabetes LONDON, November 10 /PRNewswire/ -- For Distribution to Journalists Outside the U.S. Only Findings from the Diabetes Impact Survey[a] indicate that healthcare practitioners (HCPs) thought they... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2082 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2082 Mon, 10 Nov 2008 10:00:00 +0000 Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease NOVATO, California, November 10 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2077 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2077 Mon, 10 Nov 2008 07:01:00 +0000 Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test OSLO and FOSTER CITY, California, November 10 /PRNewswire/ -- DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI) today announced the launch of BCtect(TM), a blood-based test for early... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2075 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2075 Mon, 10 Nov 2008 07:00:00 +0000 First Study in Real-Life Setting Confirms That Once-Monthly Mircera Keeps Haemoglobin Levels Within a Tight Range BASEL, Switzerland, November 10 /PRNewswire/ -- Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) maintains haemoglobin... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2074 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2074 Mon, 10 Nov 2008 06:30:00 +0000 Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death ATHENS, Greece, November 9 /PRNewswire/ -- Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2071 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2071 Sun, 09 Nov 2008 14:30:00 +0000 Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke TOKYO, November 7 /PRNewswire/ -- A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their risk for cardiovascular death, heart attack and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2070 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2070 Fri, 07 Nov 2008 15:57:00 +0000 ThromboGenics N.V.: Business Update LEUVEN, Belgium, November 6 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2064 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2064 Thu, 06 Nov 2008 16:40:00 +0000 Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients LONDON and NEW YORK, November 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2063 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2063 Thu, 06 Nov 2008 15:00:00 +0000 BioCis Pharma begins Phase IIa Trial in Atopic Dermatitis TURKU, Finland, November 6 /PRNewswire/ -- BioCis Pharma Ltd a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2061 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2061 Thu, 06 Nov 2008 12:00:00 +0000 Raptor Pharmaceuticals Provides Update on Targeting Platforms NOVATO, California, November 6 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced updates on its preclinical program which utilizes... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2060 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2060 Thu, 06 Nov 2008 11:30:00 +0000 Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) KVISTGARD, Denmark, November 6 /PRNewswire/ -- Bavarian Nordic has completed a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects that confirms the excellent... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2057 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2057 Thu, 06 Nov 2008 08:00:00 +0000 Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial CALGARY, Canada, November 4 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has made a decision to pursue a pivotal (Phase II/III) randomized... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2050 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2050 Tue, 04 Nov 2008 15:00:00 +0000 Biohit Launches New Quick Tests for Fecal Occult Blood HELSINKI, November 3 /PRNewswire/ -- Biohit is extending its range of diagnostic tests for gastrointestinal diseases with ColonView Hb and Hb/Hp quick tests, which are intended to aid early diagnosis... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2042 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2042 Mon, 03 Nov 2008 09:00:00 +0000 Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development SAN DIEGO, November 3 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2038 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2038 Mon, 03 Nov 2008 08:00:00 +0000 Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2035 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2035 Mon, 03 Nov 2008 07:01:00 +0000 Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting CALGARY, Canada, November 3 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2036 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2036 Mon, 03 Nov 2008 07:01:00 +0000 Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients BASEL, Switzerland, November 1 /PRNewswire/ -- Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2032 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2032 Sat, 01 Nov 2008 12:00:00 +0000 New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2033 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2033 Sat, 01 Nov 2008 12:00:00 +0000 Elsevier is Expanding eClinical Solutions in Europe COPENHAGEN, Denmark, October 31 /PRNewswire/ -- With a deep understanding of healthcare workflow and more than a century of experience as a global medical publisher, Elsevier is increasing its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2030 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2030 Fri, 31 Oct 2008 21:07:00 +0000 InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer BILTHOVEN and AMSTERDAM, The Netherlands, October 30 /PRNewswire/ -- InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announce today the signing of a framework research... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2021 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2021 Thu, 30 Oct 2008 07:30:00 +0000 Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 HELSINKI, October 28 /PRNewswire/ -- Northern Antibiotics Ltd., the developer of novel polymyxin derivatives for the treatment of infections caused by multidrug-resistant Gram-negative bacteria,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2003 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2003 Tue, 28 Oct 2008 16:30:00 +0000 ITERA: Storage of Umbilical Cord Stem Cells Makes Sense MAASTRICHT, Netherlands, October 28 /PRNewswire/ -- Over 70 diseases can already be successfully treated with hematopoietic (blood) stem cells and around 15 diseases are treated with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2000 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/2000 Tue, 28 Oct 2008 12:00:00 +0000 PCA3 Test May Help Distinguish Aggressive Prostate Cancer ARNHEM, The Netherlands, October 28 /PRNewswire/ -- The number of prostate cancer cases is increasing rapidly. Fortunately not all these tumours need to be operated - some are slow growing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1996 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1996 Tue, 28 Oct 2008 08:00:00 +0000 Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two WASHINGTON, October 27 /PRNewswire/ -- Data from a pivotal trial and three other Phase 3 studies presented today indicate that Wyeth's (NYSE: WYE) investigational 13-valent pneumococcal conjugate... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1991 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1991 Mon, 27 Oct 2008 15:46:00 +0000 Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting LOUISVILLE, Kentucky, October 27 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1989 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1989 Mon, 27 Oct 2008 13:36:00 +0000 World's First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada BELLEVILLE, Canada, October 27 /PRNewswire/ -- Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that Econiche(TM), the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1988 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1988 Mon, 27 Oct 2008 13:15:00 +0000 New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients MAIDENHEAD, England, October 27 /PRNewswire/ -- New safety and efficacy data for active ankylosing spondylitis (AS) patients treated with ENBREL(R) (etanercept) were presented at the American... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1985 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1985 Mon, 27 Oct 2008 07:00:00 +0000 GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology PARIS, October 24 /PRNewswire/ -- GenOdyssee (GO), a biotechnology company dedicated to the discovery and development of improved 'next generation' human protein therapeutics, announced today that it... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1981 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1981 Fri, 24 Oct 2008 14:07:00 +0000 Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting PARIS, October 24 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1978 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1978 Fri, 24 Oct 2008 12:00:00 +0000 Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology CAMBRIDGE, England, October 24 /PRNewswire/ -- Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, notes that a paper... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1977 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1977 Fri, 24 Oct 2008 10:12:00 +0000 NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device NESHER, Israel, October 23 /PRNewswire/ -- NanoVibronix, a medical device company, announced that the US Food and Drug Administration (FDA) has granted 510K clearance to market PainShield(TM) MD, a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1973 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1973 Thu, 23 Oct 2008 13:00:00 +0000 Cytochroma Announces Initiation of Phase II Clinical Trial Of CTA018 For Chronic Kidney Disease Patients MARKHAM, Canada, October 23 /PRNewswire/ -- Cytochroma today announced that it has initiated a Phase II clinical trial of CTA018 Injection, the Company's product candidate for the treatment of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1974 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1974 Thu, 23 Oct 2008 13:00:00 +0000 Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora NERVIANO, Italy, October 23 /PRNewswire/ -- Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour. A lecture focusing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1970 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1970 Thu, 23 Oct 2008 09:15:00 +0000 Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1969 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1969 Thu, 23 Oct 2008 07:30:00 +0000 Gates Foundation Invests in 104 Novel Ideas for Global Health BANGKOK, Thailand, October 22 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced 104 grants to explore bold and largely unproven ways to improve global health. The grants... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1962 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1962 Wed, 22 Oct 2008 12:00:00 +0000 New Data Confirm Consistent Efficacy and Favourable Safety Profile of Resolor(R) (Prucalopride) for Patients With Severe Chronic Constipation VIENNA, Austria, October 22 /PRNewswire/ -- New data presented at the United European Gastroenterology Week (UEGW) confirm the efficacy and safety of prucalopride, a novel enterokinetic compound, in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1963 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1963 Wed, 22 Oct 2008 12:00:00 +0000 New Issue of Diabetic Hypoglycaemia Discusses the Potential Contribution of Hypoglycaemia to the Observed Differences in Cardiac Mortality Seen in the ACCORD and ADVANCE Studies (8 October 2008) LONDON, October 22 /PRNewswire/ -- Diabetic Hypoglycaemia (http://www.hypodiab.com), the influential online diabetes journal published by ESP Bioscience, leads its new issue with a topical editorial,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1961 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1961 Wed, 22 Oct 2008 11:22:00 +0000 Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor INGELHEIM, Germany, October 22 /PRNewswire/ -- Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown encouraging results in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1960 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1960 Wed, 22 Oct 2008 11:15:00 +0000 Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment COPENHAGEN, October 22 /PRNewswire/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1959 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1959 Wed, 22 Oct 2008 11:02:00 +0000 Despite Three Months of Pain Treatment, One in Three Patients Still Suffer From Severe Chronic Pain CAMBRIDGE, England, October 22 /PRNewswire/ -- Despite treatment efforts, chronic pain management is failing one in three (n = 377) patients suffering from severe chronic pain, and three in five (n =... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1955 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1955 Wed, 22 Oct 2008 00:01:00 +0000 New Pharmaceutical Company to Target Alzheimer's Disease SARASOTA, Florida, October 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1954 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1954 Tue, 21 Oct 2008 21:00:00 +0000 New Research From the "Elephant Man" Trial Highlights the Need for EU Legislation to Ensure That Information Given to People Enrolling on Clinical Trials is Easily Understood LEEDS, England, October 22 /PRNewswire/ -- New research presented today shows that the information given to the volunteers of the disastrous Northwick Park "Elephant Man" trial would not have passed... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1953 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1953 Tue, 21 Oct 2008 19:00:00 +0000 New Treatment for People with Epilepsy LONDON, October 21 /PRNewswire/ -- Vimpat (lacosamide), a new treatment for adults with partial onset epilepsy, and which is to be used as an add-on to patients' current therapy, has been launched in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1938 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1938 Mon, 20 Oct 2008 12:19:00 +0000 Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH) NOVATO, California, October 20 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the initiation of patient dosing in a Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1935 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1935 Mon, 20 Oct 2008 11:30:00 +0000 Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System SUNNYVALE, California, October 20 /PRNewswire/ -- BARRX Medical, Inc. today announced clinical trial results presented at the United European Gastroenterology Week (UEGW) in Vienna, Austria,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1931 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1931 Mon, 20 Oct 2008 02:00:00 +0000 From Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes INGELHEIM and BIBERACH, Germany, October 17 /PRNewswire/ -- Boehringer Ingelheim announced that patients and physicians may have several innovative type 2 diabetes treatment alternatives available in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1928 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1928 Fri, 17 Oct 2008 11:30:00 +0000 InspireMD, Developers of the Novel MGuard(TM) Coronary Stent System, Celebrates Unprecedented Success at the GISE 24th National Congress of the Italian Society of Invasive Cardiology in Bologna, Italy TEL AVIV, Israel, October 15 /PRNewswire/ -- InspireMD, Ltd. announced that the MGuard(TM) coronary stent system was celebrated by hundreds of Italy's leading cardiologists at the GISE 24th National... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1923 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1923 Wed, 15 Oct 2008 15:17:00 +0000 Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) WASHINGTON, October 14 /PRNewswire/ -- OrbusNeich today announced that an interim analysis of 12-month follow-up data from the global e-HEALING registry show good safety and efficacy in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1912 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1912 Tue, 14 Oct 2008 10:30:00 +0000 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions WASHINGTON, October 13 /PRNewswire/ -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1908 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1908 Mon, 13 Oct 2008 16:36:00 +0000 Genmab Reaches Milestone in Ofatumumab Collaboration COPENHAGEN, Denmark, October 10 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1899 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1899 Fri, 10 Oct 2008 16:06:00 +0000 Evalve Expands Executive Leadership Team MENLO PARK, California, October 9 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, has expanded its sales and marketing executive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1891 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1891 Thu, 09 Oct 2008 15:00:00 +0000 Diamyd(R) Study Published in Prestigious New England Journal of Medicine STOCKHOLM, October 9 /PRNewswire/ -- Diamyd Medical reports that the world's most influential medical journal, the New England Journal of Medicine, has published an article with results from the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1888 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1888 Thu, 09 Oct 2008 06:00:00 +0000 MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe ASHLAND, Massachusetts, October 8 /PRNewswire/ -- MatTek Corp. today announced that results of a recently completed US and European multi-laboratory "catch-up" validation study on MatTek's EpiDerm... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1886 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1886 Wed, 08 Oct 2008 21:19:00 +0000 Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio COPENHAGEN, October 8 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1884 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1884 Wed, 08 Oct 2008 15:31:00 +0000 Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc REDMOND, Washington, October 8 /PRNewswire/ -- Archus Orthopedics, Inc. today announced the first human use of its facet replacement technology to complement an artificial disc. The landmark case was... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1880 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1880 Wed, 08 Oct 2008 13:13:00 +0000 Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress SAN DIEGO, October 8 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1879 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1879 Wed, 08 Oct 2008 12:30:00 +0000 Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection SUNNYVALE, California, October 7 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(TM) vanA/vanB as a European CE IVD Mark product under the European Directive on In... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1873 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1873 Tue, 07 Oct 2008 12:00:00 +0000 LENTE Clinic Announces First Patients Treated With the Advance(TM) System for Obstructive Sleep Apnea PLZEN, Czech Republic, October 7 /PRNewswire/ -- LENTE Clinic announced today that it had successfully treated its first patients with the third-generation Advance System implant for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1870 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1870 Tue, 07 Oct 2008 08:00:00 +0000 Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine KVISTG http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1869 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1869 Tue, 07 Oct 2008 07:15:00 +0000 Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics BILLERICA, Massachusetts, October 6 /PRNewswire/ -- Seahorse Bioscience today announced the release of the first ever analytical instrument for the kinetic measurement of mitochondrial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1865 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1865 Mon, 06 Oct 2008 16:30:00 +0000 Botaneco Receives Natural Ingredient Approval From ECOCERT(R) for Hydresia(TM) G2 CALGARY, Canada, October 6 /PRNewswire/ -- TSX symbol: SBS Botaneco Specialty Ingredients Inc. (Botaneco), a subsidiary of SemBioSys Genetics Inc. (SemBioSys), today announced that its second... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1861 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1861 Mon, 06 Oct 2008 12:22:00 +0000 Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 HONG KONG, October 6 /PRNewswire/ -- Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1858 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1858 Mon, 06 Oct 2008 10:30:00 +0000 AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) AMSTERDAM, October 3 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it intends to incorporate additional data into... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1854 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1854 Fri, 03 Oct 2008 17:49:00 +0000 Severe Adverse Event Reported in Raptiva(R) Patient GENEVA, Switzerland, October 2 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Genentech Inc. has reported a case of progressive multifocal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1849 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1849 Thu, 02 Oct 2008 23:11:00 +0000 Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1848 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1848 Thu, 02 Oct 2008 14:16:00 +0000 Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay REHOVOT, Israel and JERSEY CITY, New Jersey, October 2 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1847 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1847 Thu, 02 Oct 2008 13:30:00 +0000 Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced today that they have entered into a collaboration to discover and to develop therapeutic products... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1845 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1845 Thu, 02 Oct 2008 12:30:00 +0000 Bayer's Novel Oral Anticoagulant Xarelto(R) (Rivaroxaban) Gets European Licence NEWBURY, England, October 2 /PRNewswire/ -- A new drug launched today could help in the fight against what experts and campaigners are calling a 'major patient safety issue'(1) - the prevention of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1842 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1842 Thu, 02 Oct 2008 11:35:00 +0000 ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases HALIFAX, Canada, October 1 /PRNewswire/ -- ImmunoVaccine Technologies' (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1838 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1838 Wed, 01 Oct 2008 14:00:00 +0000 Evalve Announces Enrollment Completion of the EVEREST Randomized Study MENLO PARK, California, September 30 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the completion of randomized... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1828 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1828 Tue, 30 Sep 2008 15:00:00 +0000 ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin LEUVEN, Belgium, September 29 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1817 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1817 Mon, 29 Sep 2008 06:00:00 +0000 Merck Serono's Kuvan(R) Recommended for European Approval GENEVA, Switzerland, September 26 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the Committee for Medicinal Products for Human Use (CHMP), the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1811 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1811 Fri, 26 Sep 2008 07:30:00 +0000 Landmark Campaign Reaches Rural Kenyans with Tools to Prevent Malaria, Diarrhoeal Disease and HIV KAKAMEGA, Kenya, September 26 /PRNewswire/ -- An important new approach to fighting malaria, diarrhoeal disease and HIV among adult men and women aged 15-49 has successfully been demonstrated for the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1808 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1808 Fri, 26 Sep 2008 01:07:00 +0000 Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window INGELHEIM, Germany, September 25 /PRNewswire/ -- First results from ECASS 3 (European Cooperative Acute Stroke Study) were presented today at the 6th World Stroke Congress in Vienna, Austria,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1803 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1803 Thu, 25 Sep 2008 08:30:00 +0000 Landmark UPLIFT Study Reaffirms the Safety of Spiriva (tiotropium) in Patients With Chronic Obstructive Pulmonary Disease LEUVEN, Belgium, September 24 /PRNewswire/ -- Placebo-controlled, randomised, double-blind clinical trials provide the most comprehensive and strongest evidence of a drug's safety profile.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1799 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1799 Wed, 24 Sep 2008 16:10:00 +0000 New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy PORTO, Portugal, September 24 /PRNewswire/ -- Positive data from three phase III studies presented today at the 8th European Congress of Epileptology, Berlin, Germany, demonstrated that Zebinix(TM)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1798 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1798 Wed, 24 Sep 2008 16:00:00 +0000 Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years LONDON, September 24 /PRNewswire/ -- Clinicians and patient groups have welcomed today's announcement by the National Institute of Health and Clinical Excellence (NICE) recommending Pradaxa(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1793 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1793 Wed, 24 Sep 2008 08:23:00 +0000 Recruitment Completed in Ofatumumab NHL Pivotal Study COPENHAGEN, September 23 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1790 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1790 Tue, 23 Sep 2008 17:14:00 +0000 Canadian-Made Life Saving HIV/AIDS Drug Heading to Africa Under Canada's Access to Medicines Regime (CAMR) TORONTO, September 23 /PRNewswire/ -- Apotex Inc, the largest Canadian-owned pharmaceutical company, is pleased to announce that Apo-TriAvir, a triple combination HIV/AIDS drug, approved under... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1787 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1787 Tue, 23 Sep 2008 15:00:00 +0000 Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins COLLEGEVILLE, Pennsylvania, September 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the Community Acquired Pneumonia Immunization Trial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1785 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1785 Tue, 23 Sep 2008 14:11:00 +0000 Merck Serono Announces One-Month Results of Pharmacogenomics Study PREDICT at 47th Annual Meeting of the European Society for Paediatric Endocrinology GENEVA, Switzerland, September 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today presented the results of the PREDICT study at the 47th Annual Meeting of the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1783 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1783 Tue, 23 Sep 2008 13:00:00 +0000 InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results TEL AVIV, Israel, September 23 /PRNewswire/ -- InspireMD, Ltd. announced today the enrollment of the first 3 patients in its study of MGuard(TM) coronary stent in acute myocardial infarction.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1781 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1781 Tue, 23 Sep 2008 12:00:00 +0000 Concentric Medical to Sponsor Randomized Trial MOUNTAIN VIEW, California, September 23 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced its plan to sponsor... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1780 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1780 Tue, 23 Sep 2008 11:00:00 +0000 Recruitment Completed in Ofatumumab NHL Front Line Study COPENHAGEN, September 22 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1776 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1776 Mon, 22 Sep 2008 13:09:00 +0000 Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts AURORA, Ontario, September 22 /PRNewswire/ -- Helix BioPharma announced today that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1775 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1775 Mon, 22 Sep 2008 13:00:00 +0000 Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis GENEVA, Switzerland, September 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1771 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1771 Mon, 22 Sep 2008 07:00:00 +0000 First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease VENLO, Netherlands, September 21 /PRNewswire/ -- A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more accurate in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1767 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1767 Sun, 21 Sep 2008 23:31:00 +0000 Hospitals Must Take up Challenge to Tackle Clots LONDON, September 19 /PRNewswire/ -- A new tool to help hospital doctors screen for Britain's most dangerous hospital killer is being rolled out across the country today and has the potential to save... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1762 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1762 Fri, 19 Sep 2008 11:51:00 +0000 Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1759 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1759 Thu, 18 Sep 2008 13:00:00 +0000 Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life MAIDENHEAD, England, September 18 /PRNewswire/ -- Data demonstrating the significant positive impact of Enbrel (etanercept) on the quality of life of psoriasis patients were presented today at the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1757 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1757 Thu, 18 Sep 2008 12:00:00 +0000 Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment PARIS, September 18 /PRNewswire/ -- More psoriasis patients achieve efficacy when they receive continuous treatment with HUMIRA(R) (adalimumab) compared to patients who interrupt their therapy,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1754 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1754 Thu, 18 Sep 2008 11:00:00 +0000 AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform AMSTERDAM, The Netherlands, September 18 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1750 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1750 Thu, 18 Sep 2008 07:08:00 +0000 Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis GENEVA, Switzerland, September 18 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the initiation of a Phase III trial to evaluate the therapeutic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1749 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1749 Thu, 18 Sep 2008 07:00:00 +0000 Latest RAD001 Study Results Show Further Increase in Time Without Tumour Growth in Patients With Advanced Kidney Cancer FRIMLEY, England, September 17 /PRNewswire/ -- New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1745 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1745 Wed, 17 Sep 2008 13:50:00 +0000 RAD001 Combined With Sandostatin(R) LAR(R) and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumours FRIMLEY, England, September 17 /PRNewswire/ -- New data show that combination treatment with RAD001 (everolimus) and Sandostatin(R) LAR(R) (octreotide IM) and RAD001 given alone control tumour... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1744 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1744 Wed, 17 Sep 2008 13:43:00 +0000 Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America DUBLIN, Ireland and NEWCASTLE, England, September 17 /PRNewswire/ -- Cambridge Laboratories Group Limited ("Cambridge" or the "Company"), the privately-owned specialty pharmaceutical company,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1743 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1743 Wed, 17 Sep 2008 12:59:00 +0000 Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis GENEVA, Switzerland, September 17 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX trial (REbif... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1740 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1740 Wed, 17 Sep 2008 07:00:00 +0000 Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes NEW YORK and LONDON, September 16 /PRNewswire/ -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1738 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1738 Tue, 16 Sep 2008 22:48:00 +0000 Data From Three Trials Support Evidence of Zometa(R) Anticancer Benefit in Pre- and Post-Menopausal Women With Early-Stage Breast Cancer FRIMLEY, England, September 16 /PRNewswire/ -- New data from three clinical trials show Zometa(R) (zoledronic acid) reduced the risk of local and distant recurrence in pre- and post-menopausal women... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1737 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1737 Tue, 16 Sep 2008 18:46:00 +0000 SemBioSys Eligible to Proceed With Phase I/II Plant-Produced Insulin Trial After Submission of IND CALGARY, Canada, September 16 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1734 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1734 Tue, 16 Sep 2008 14:47:00 +0000 InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies BRITISH COLUMBIA, Canada, September 16 /PRNewswire/ -- InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com), a drug development company commercializing the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1732 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1732 Tue, 16 Sep 2008 14:32:00 +0000 Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations NYON, Switzerland, September 16 /PRNewswire/ -- Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1731 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1731 Tue, 16 Sep 2008 13:00:00 +0000 DSM Nutritional Products: Fending off Dementia: Beta-Carotene Shown to Improve Memory KAISERAUGST, Switzerland, September 16 /PRNewswire/ -- A new scientific study has shown that consuming Beta-carotene over a long period of time may help to preserve mental fitness by improving how... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1728 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1728 Tue, 16 Sep 2008 10:15:00 +0000 New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status BASEL, Switzerland, September 16 /PRNewswire/ -- Avastin (bevacizumab) remains the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1724 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1724 Tue, 16 Sep 2008 07:30:00 +0000 AVAiL Study Shows Longest Survival in Patients With Advanced Non-Small Cell Lung Cancer BASEL, Switzerland, September 15 /PRNewswire/ -- The final analysis of the Avastin in lung study (AVAiL) in patients with advanced lung cancer has shown that not only did the drug significantly... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1721 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1721 Mon, 15 Sep 2008 14:25:00 +0000 Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R) WELLESLEY HILLS, Massachusetts, September 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1720 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1720 Mon, 15 Sep 2008 14:00:00 +0000 Pan-European Research Reveals Majority of Osteoporosis Patients not Receiving Recommended Combination of Calcium and Vitamin D With Treatment GENEVA, September 15 /PRNewswire/ -- New research published today at the annual meeting of the American Society for Bone and Mineral Research (ASBMR), Montr http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1717 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1717 Mon, 15 Sep 2008 09:30:00 +0000 Palonosetron: The Long-Lasting Antiemetic Action Finds its Basis STOCKHOLM, Sweden, September 12 /PRNewswire/ -- New data presented today at the 33rd ESMO (European Society of Medical Oncology) Congress in Stockholm may contribute to explain the reason... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1712 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1712 Fri, 12 Sep 2008 16:00:00 +0000 Sun Pharma Gets USFDA Approval for Generic Fosamax (R) Tablets MUMBAI, India, September 12 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted final approval for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1711 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1711 Fri, 12 Sep 2008 13:55:00 +0000 Avastin(R) Continues to Demonstrate Long Term Survival for Patients With Metastatic Colorectal Cancer BASEL, Switzerland, September 12 /PRNewswire/ -- Avastin's (bevacizumab) essential role in the treatment of patients with metastatic colorectal cancer (mCRC), the world's second most common... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1709 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1709 Fri, 12 Sep 2008 08:00:00 +0000 Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs INGELHEIM, Germany, September 11 /PRNewswire/ -- Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended happy life together for millions of dog owners... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1704 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1704 Thu, 11 Sep 2008 07:00:00 +0000 Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin PARIS, September 10 /PRNewswire/ -- Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1700 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1700 Wed, 10 Sep 2008 15:00:00 +0000 Roche to Present Data Showing Progress in Treating Lung, Gastric and Brain Cancers at ESMO BASEL, Switzerland, September 10 /PRNewswire/ -- More than 100 Roche abstracts have been accepted for the biggest cancer congress in Europe, the European Society for Medical Oncology (ESMO),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1691 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1691 Wed, 10 Sep 2008 06:30:00 +0000 First Reported Head-to-Head Study Showed BYETTA(R) (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia(TM) (sitagliptin) in Patients With Type 2 Diabetes ROME, September 9 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a randomized, double-blind, cross-over, four-week... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1685 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1685 Tue, 09 Sep 2008 12:30:00 +0000 New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment ROME, September 9 /PRNewswire/ -- Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that saxagliptin, an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1684 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1684 Tue, 09 Sep 2008 11:29:00 +0000 BioCis Pharma Receives 1.6 Million EURO New Financing to Speed the Clinical Phase I/II Programme of the Company's Dermatology Product TURKU, Finland, September 9 /PRNewswire/ -- BioCis Pharma Ltd announced that it has received almost 1.6 million EURO new R&D financing. The money is specifically targeted for the clinical testing... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1681 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1681 Tue, 09 Sep 2008 08:00:00 +0000 Nucletron Announces Advances in Image-Guided Adaptive Brachytherapy Technology for Gynecologic Cancers Through Partnership With AKH / MUW Vienna VEENENDAAL, Netherlands, September 9 /PRNewswire/ -- Nucletron, a knowledge-based leader in radiation oncology, and the world-class medical institution General Hospital Vienna (AKH) /... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1682 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1682 Tue, 09 Sep 2008 08:00:00 +0000 Fenofibrate Reduces the Risk of Amputations in Patients With Type 2 Diabetes ROME, September 9 /PRNewswire/ -- Fenofibrate treatment in people with type 2 diabetes mellitus reduces the risk of amputations, including those associated with microvascular disease, according to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1683 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1683 Tue, 09 Sep 2008 08:00:00 +0000 New HIV Protection for Women MANCHESTER, England, September 9 /PRNewswire/ -- Vaginal rings, similar to those used for contraception and hormone replacement therapy, could protect women from sexually-transmitted HIV, according... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1673 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1673 Tue, 09 Sep 2008 00:01:00 +0000 Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination With Paclitaxel and Carboplatin CALGARY, Canada, September 8 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase 2 clinical trial using... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1671 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1671 Mon, 08 Sep 2008 17:10:00 +0000 Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes ROME, September 8 /PRNewswire/ -- Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrate that saxagliptin, an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1668 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1668 Mon, 08 Sep 2008 13:38:00 +0000 VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma HIGH WYCOMBE, England, September 8 /PRNewswire/ -- Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced the European Commission's approval of VELCADE in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1666 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1666 Mon, 08 Sep 2008 11:20:00 +0000 ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications ZURICH, Switzerland, September 8 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has successfully completed its Phase I... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1664 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1664 Mon, 08 Sep 2008 08:01:00 +0000 Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 LONDON, September 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1649 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1649 Sat, 06 Sep 2008 08:45:00 +0000 Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL COPENHAGEN, Denmark, September 5 /PRNewswire/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1642 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1642 Fri, 05 Sep 2008 15:51:00 +0000 Migraine With Aura may be Linked to Increased Risk of Stroke and Heart Attacks and Must be Taken Seriously by GPs LONDON, September 5 /PRNewswire/ -- Doctors need to pay special attention to people with migraine with aura as they could be at increased risk of stroke or heart attack, a London conference heard... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1641 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1641 Fri, 05 Sep 2008 10:00:00 +0000 Agendia Launches TargetPrint(R) for Breast Cancer Patients HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 4 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint(R), a new... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1633 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1633 Thu, 04 Sep 2008 13:00:00 +0000 Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel MUNICH, Germany, September 3 /PRNewswire/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1618 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1618 Wed, 03 Sep 2008 08:16:00 +0000 New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses MUNICH, Germany, September 3 /PRNewswire/ -- Among patients with acute coronary syndromes (ACS) who are administered a 900 mg loading dose of clopidogrel, does a maintenance dose of 150 mg... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1617 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1617 Wed, 03 Sep 2008 07:46:00 +0000 Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation PARIS, September 3 /PRNewswire/ -- The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1616 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1616 Wed, 03 Sep 2008 07:30:00 +0000 Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies CARLSBAD, California, September 2 /PRNewswire/ -- Ablation Frontiers, Inc., announced today that two important studies, involving its innovative atrial fibrillation ablation products were... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1614 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1614 Tue, 02 Sep 2008 19:59:00 +0000 n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure MUNICH - ESC Congress 2008, September 2 /PRNewswire/ -- For the first time, results from a new landmark trial of purified n-3 polyunsaturated fatty acids (n-3 PUFAs) were presented at one of the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1610 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1610 Tue, 02 Sep 2008 14:58:00 +0000 Stem Cell Sciences Announces the Creation of the World's First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology CAMBRIDGE, England, September 2 /PRNewswire/ -- Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1609 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1609 Tue, 02 Sep 2008 13:00:00 +0000 VIVIMIND(TM), Canada's Scientifically Proven Natural Health Product to Protect Memory Function, is Available Starting Today LAVAL, Quebec, September 2 /PRNewswire/ -- OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU), announces that VIVIMIND(TM), the company's first natural... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1607 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1607 Tue, 02 Sep 2008 12:01:00 +0000 Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients With K-RAS or EGFR-Activated Tumours CALGARY, Canada, September 2 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1606 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1606 Tue, 02 Sep 2008 07:01:00 +0000 SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI WASHINGTON, September 1 /PRNewswire/ -- Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced today from the CARDia trial,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1605 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1605 Mon, 01 Sep 2008 13:45:00 +0000 SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease WASHINGTON, September 1 /PRNewswire/ -- Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease can safely choose to be treated with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1604 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1604 Mon, 01 Sep 2008 13:35:00 +0000 Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study MUNICH, Germany, September 1 /PRNewswire/ -- Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1603 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1603 Mon, 01 Sep 2008 11:30:00 +0000 American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation MONTPELLIER, France, September 1 /PRNewswire/ -- The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1601 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1601 Mon, 01 Sep 2008 05:30:00 +0000 British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines BURGESS HILL, England, September 1 /PRNewswire/ -- With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1599 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1599 Mon, 01 Sep 2008 00:01:00 +0000 Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel MUNICH, Germany, August 31 /PRNewswire/ -- Patients who were diabetic and diagnosed with acute coronary syndromes (ACS) were 40 percent less likely to suffer a heart attack if they were treated with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1598 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1598 Sun, 31 Aug 2008 14:31:00 +0000 INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy CORK, Ireland, August 29 /PRNewswire/ -- -INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI-Resistant Virus The European Medicines Agency (EMEA) has granted... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1595 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1595 Fri, 29 Aug 2008 15:03:00 +0000 Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B UXBRIDGE, England, August 29 /PRNewswire/ -- NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude(R) (entecavir) as an option for treatment of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1594 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1594 Fri, 29 Aug 2008 11:02:00 +0000 New Research Reveals That Mycamine(R) is an Effective Treatment in Children, Young Babies and Premature Infants STAINES, England, August 28 /PRNewswire/ -- Parents and paediatricians are today welcoming the results of new research that adds additional support for an effective and well tolerated treatment for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1592 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1592 Thu, 28 Aug 2008 18:30:00 +0000 Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin OSLO, August 28 /PRNewswire/ -- Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1589 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1589 Thu, 28 Aug 2008 10:22:00 +0000 Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber ANTONY, France, August 27 /PRNewswire/ -- Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC). The study on Oralair(R) Grasses... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1582 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1582 Wed, 27 Aug 2008 19:00:00 +0000 Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) for wet AMD FRIMLEY, England, August 27 /PRNewswire/ -- Novartis Pharmaceuticals UK Ltd (Novartis) today welcomed the Final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1571 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1571 Tue, 26 Aug 2008 16:52:00 +0000 Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program ROCKVILLE, Maryland, August 26 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1568 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1568 Tue, 26 Aug 2008 13:00:00 +0000 Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels WELLESLEY HILLS, Massachusetts, August 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1561 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1561 Mon, 25 Aug 2008 17:01:00 +0000 Phase 1b/2a Program Commences for RVX-208 CALGARY, Canada, August 25 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1560 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1560 Mon, 25 Aug 2008 15:03:00 +0000 Genmab Announces Upcoming Ofatumumab Studies COPENHAGEN, Denmark, August 25 /PRNewswire/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Genmab A/S (OMX: GEN)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1557 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1557 Mon, 25 Aug 2008 08:40:00 +0000 Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test HAMBURG, Germany, August 22 /PRNewswire/ -- Sometimes something well-tried can also be innovative: already in Ancient Greece, copper was considered to be very antimicrobial. This ability is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1555 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1555 Fri, 22 Aug 2008 13:04:00 +0000 Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events TOKYO and INDIANAPOLIS, August 21 /PRNewswire/ -- A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1551 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1551 Thu, 21 Aug 2008 13:00:00 +0000 Shingles Pain Treatment Will Benefit More Patients LONDON, August 21 /PRNewswire/ -- The medicated pain relief plaster, (Versatis) is now approved by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for patients... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1550 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1550 Thu, 21 Aug 2008 12:26:00 +0000 Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 KVISTGARD, Denmark, August 19 /PRNewswire/ -- Today Bavarian Nordic published the company's interim report as of 30 June 2008. The full financial statements are available on the company's website.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1541 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1541 Tue, 19 Aug 2008 08:35:00 +0000 Cambridge Laboratories Announces FDA Approval of XENAZINE(R) (tetrabenazine) in the US LONDON, August 18 /PRNewswire/ -- Cambridge Laboratories Group Limited ("Cambridge"), the privately owned specialty pharmaceutical company, announces today that XENAZINE(R) (tetrabenazine), the first... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1538 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1538 Mon, 18 Aug 2008 07:00:00 +0000 Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer MUMBAI, India, August 14 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced that on August 13, 2008, the U.S.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1520 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1520 Thu, 14 Aug 2008 09:33:00 +0000 Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer MUMBAI, India, August 14 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced that on August 13, 2008, the U.S.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1534 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1534 Thu, 14 Aug 2008 09:33:00 +0000 BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis EDMONTON, Canada, August 13 /PRNewswire/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Drug Safety... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1519 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1519 Wed, 13 Aug 2008 21:49:00 +0000 BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis EDMONTON, Canada, August 13 /PRNewswire/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Drug Safety... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1533 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1533 Wed, 13 Aug 2008 21:49:00 +0000 Cryotherapy: A Novel Treatment Option for Prostate Cancer LONDON, August 12 /PRNewswire/ -- Each year nearly 33,000 men in the UK are diagnosed with prostate cancer and more than 10,000 die from the disease. It has become the most common cancer in men and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1504 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1504 Tue, 12 Aug 2008 10:35:00 +0000 Cryotherapy: A Novel Treatment Option for Prostate Cancer LONDON, August 12 /PRNewswire/ -- Each year nearly 33,000 men in the UK are diagnosed with prostate cancer and more than 10,000 die from the disease. It has become the most common cancer in men and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1521 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1521 Tue, 12 Aug 2008 10:35:00 +0000 ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease KIRKLAND, Washington, August 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1500 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1500 Thu, 07 Aug 2008 14:00:00 +0000 ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing ZURICH, Switzerland, August 7 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M (USD 22M, EUR 14M)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1498 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1498 Thu, 07 Aug 2008 06:00:00 +0000 Heart Patient Living With Implantable Heart Support System for Five Years BERLIN, August 6 /PRNewswire/ -- A 64-year-old man from France is the patient with the longest support time worldwide by the implantable heart support system INCOR(R). For five years already the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1494 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1494 Wed, 06 Aug 2008 12:57:00 +0000 Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines MEXICO CITY, August 5 /PRNewswire/ -- Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1491 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1491 Tue, 05 Aug 2008 20:20:00 +0000 TMC278 Demonstrates Long-Term Efficacy and Tolerability in Treatment-Naïve Adults With HIV MEXICO CITY, Mexico, August 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1489 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1489 Tue, 05 Aug 2008 17:20:00 +0000 Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study COPENHAGEN, July 31 /PRNewswire/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1475 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1475 Thu, 31 Jul 2008 17:17:00 +0000 MabThera Filed in the EU for Treatment of Most Common Leukaemia in Adults BASEL, Switzerland, July 31 /PRNewswire/ -- Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1472 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1472 Thu, 31 Jul 2008 11:35:00 +0000 SemBioSys Submits IND for Safflower-Produced Insulin to U.S. FDA CALGARY, July 29 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1458 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1458 Tue, 29 Jul 2008 12:00:00 +0000 Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial SAN DIEGO, July 28 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1451 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1451 Mon, 28 Jul 2008 12:30:00 +0000 Studies Assessed by European Health Authority Conclude That Impurity in Roche's Viracept(R) (nelfinavir mesylate) Did Not Increase Patient's Risk of Cancer BASEL, Switzerland, July 24 /PRNewswire/ -- The European Committee for Human Medicinal Products (CHMP) has confirmed that the presence of an impurity called ethyl methanesulfonate (EMS) in Roche's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1445 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1445 Thu, 24 Jul 2008 16:01:00 +0000 InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1440 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1440 Wed, 23 Jul 2008 15:48:00 +0000 First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval REHOVOT, Israel and JERSEY CITY, New Jersey, July 22 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announces today that the first molecular test based on Rosetta Genomics' proprietary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1434 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1434 Tue, 22 Jul 2008 13:30:00 +0000 Milestone for Cannabinoid MS Study LONDON, July 21 /PRNewswire/ -- The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School has reached an important milestone with the news that the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1424 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1424 Mon, 21 Jul 2008 13:20:00 +0000 Update on the SEAS Study LONDON, July 21 /PRNewswire/ -- Professor Terje Pedersen (Ullevål University Hospital, Oslo, Norway), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study, will provide... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1419 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1419 Mon, 21 Jul 2008 08:00:00 +0000 Max Planck Society Awards Exclusive License to Dafra Pharma R&D to Develop a Drug Against Leishmaniasis TURNHOUT, Belgium, July 16 /PRNewswire/ -- Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1401 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1401 Wed, 16 Jul 2008 12:26:00 +0000 Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050 FREISING-WEIHENSTEPHAN and JENA, Germany, July 16 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, and Wacker... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1398 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1398 Wed, 16 Jul 2008 09:00:00 +0000 EyeGate Pharma Initiates Landmark Clinical Study Employing the EyeGate(R) II Non-Invasive Ocular Delivery System in Acute Anterior Uveitis WALTHAM, Massachusetts, July 15 /PRNewswire/ -- EyeGate Pharma, a privately held specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1395 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1395 Tue, 15 Jul 2008 13:01:00 +0000 Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study COPENHAGEN, Denmark, July 9 /PRNewswire/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1372 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1372 Wed, 09 Jul 2008 23:18:00 +0000 Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain REHOVOT, Israel and JERSEY CITY, New Jersey, July 9 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1368 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1368 Wed, 09 Jul 2008 13:30:00 +0000 Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules MAIDENHEAD, England, July 8 /PRNewswire/ -- Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their decisions to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1360 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1360 Tue, 08 Jul 2008 17:49:00 +0000 National Institute for Health and Clinical Excellence (NICE) Final Appraisal Determination Recommends Treatment Options for Primary and Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women EGHAM, England, July 8 /PRNewswire/ -- Procter & Gamble Pharmaceuticals (P&GP) welcome the new Final Appraisal Determination (FAD) Guidance for the primary and secondary prevention of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1359 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1359 Tue, 08 Jul 2008 17:24:00 +0000 European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients MAIDENHEAD, England, July 7 /PRNewswire/ -- Wyeth Pharmaceuticals, today 3rd July, announced that it has received EMEA marketing approval for Relistor(TM) (methylnaltrexone bromide) subcutaneous... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1356 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1356 Mon, 07 Jul 2008 18:56:00 +0000 Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data presented recently at the 17th Annual Meeting of the Japanese Society of Interventional Cardiology demonstrate that the Genous... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1354 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1354 Mon, 07 Jul 2008 15:41:00 +0000 BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections SAN DIEGO, July 7 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the CE marking of the BD GeneOhm(TM) Cdiff molecular assay for the rapid... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1351 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1351 Mon, 07 Jul 2008 05:01:00 +0000 Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in Cirrhotic Ascites TURNHOUT, Belgium, July 3 /PRNewswire/ -- Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1340 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1340 Thu, 03 Jul 2008 11:42:00 +0000 Shire to Add New Orphan Drug to its HGT Portfolio - EU Launch Imminent BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 3 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1338 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1338 Thu, 03 Jul 2008 08:30:00 +0000 Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity HELSINKI, July 1 /PRNewswire/ -- The emergence of multidrug-resistant Gram-negative bacteria has necessitated the use of polymyxins as the agents of last resort despite their known nephrotoxicity.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1330 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1330 Tue, 01 Jul 2008 12:17:00 +0000 Silence Therapeutics Announces Board Changes LONDON, July 1 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN) ('the Company') today announced changes to its Board of Directors as part of the company's plan for growth. Effective... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1329 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1329 Tue, 01 Jul 2008 12:00:00 +0000 EMEA Confirms Positive Benefit-Risk Balance With Raptiva(R) for the Treatment of Psoriasis GENEVA, Switzerland, July 1 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Commission has approved an update of the Summary of Product... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1328 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1328 Tue, 01 Jul 2008 11:07:00 +0000 Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial ROTTERDAM, Netherlands and DOYLESTOWN, Pennsylvania, July 1 /PRNewswire/ -- An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1327 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1327 Tue, 01 Jul 2008 08:00:00 +0000 Genmab Reaches Milestone in Ofatumumab Collaboration COPENHAGEN, June 30 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1324 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1324 Mon, 30 Jun 2008 18:27:00 +0000 Honda to Conduct Collaborative Testing of its Walking Assist Device TOKYO, June 30 /PRNewswire/ -- Honda Motor Co., Ltd. will begin collaborative testing of its experimental walking assist device as from July 1, 2008, with Shinseikai Medical Group,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1318 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1318 Mon, 30 Jun 2008 09:06:00 +0000 Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children PARIS, June 30 /PRNewswire/ -- Five years after the identification of the gene responsible for progeria, a rare disease causing accelerated and premature ageing, a team of Spanish and French... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1316 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1316 Mon, 30 Jun 2008 09:00:00 +0000 /C O R R E C T I O N -- AFM-Association Francaise contre les Myopathies/ PARIS, June 30 /PRNewswire/ -- In the news release, "Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children" issued on 30 Jun 2008 08:00 GMT, by... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1317 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1317 Mon, 30 Jun 2008 09:00:00 +0000 Microscopic Needles Could Revolutionise Eye Treatment LONDON, June 30 /PRNewswire/ -- A new technique that effectively delivers drugs to the eyes, using microscopic needles, could offer hope to the millions of patients worldwide suffering from common... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1313 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1313 Mon, 30 Jun 2008 00:01:00 +0000 Prostate Cancer: NICE Clarification Boosts NHS Treatment Options LONDON, June 27 /PRNewswire/ -- Physician experts at the British Association of Urological Surgeons' (BAUS) annual meeting this week heard how discussions with NICE have opened the way for patients... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1312 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1312 Fri, 27 Jun 2008 16:20:00 +0000 ProStrakan Group plc: Abstral (Rapinyl) Receives Positive CHMP Opinion for Breakthrough Cancer Pain GALASHIELS, Scotland, June 27 /PRNewswire/ -- ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the Committee for Medicinal Products for Human Use... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1308 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1308 Fri, 27 Jun 2008 09:09:00 +0000 European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment BASEL, Switzerland, June 26 /PRNewswire/ -- Roche announced today that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1301 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1301 Thu, 26 Jun 2008 07:00:00 +0000 Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial ANN ARBOR, Michigan, June 25 /PRNewswire/ -- Terumo Heart, Inc. announced today approval from the Institutional Review Board (IRB) at the University of Michigan to move forward with the DuraHeart(TM)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1294 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1294 Wed, 25 Jun 2008 14:07:00 +0000 Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics REHOVOT, Israel and JERSEY CITY, New Jersey, June 25 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG), announced today a collaboration with the Rabin Medical Center in Israel to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1293 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1293 Wed, 25 Jun 2008 13:30:00 +0000 NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis MAIDENHEAD, England, June 25 /PRNewswire/ -- The National Institute for Health and Clinical Excellence (NICE) today recommended adalimumab (HUMIRA) as a treatment option for adults with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1287 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1287 Wed, 25 Jun 2008 00:01:00 +0000 Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer COPENHAGEN, June 24 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1285 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1285 Tue, 24 Jun 2008 21:24:00 +0000 Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times CARLSBAD, California, June 24 /PRNewswire/ -- Ablation Frontiers, Inc. today announced that two studies reporting positive findings about its novel atrial fibrillation catheter ablation system were... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1282 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1282 Tue, 24 Jun 2008 19:41:00 +0000 Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis LONDON, June 24 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has initiated a Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1278 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1278 Tue, 24 Jun 2008 16:20:00 +0000 Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody NEW YORK, June 24 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) and MRC Technology (MRCT) announced today they have achieved an important milestone through their... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1276 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1276 Tue, 24 Jun 2008 11:00:00 +0000 European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naïve HIV-1 Infected Adults PARIS, June 24 /PRNewswire/ -- The European Commission has granted marketing authorization for REYATAZ(R) (atazanavir sulfate 300mg once daily), administered with ritonavir 100 mg once daily and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1271 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1271 Tue, 24 Jun 2008 06:30:00 +0000 CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck LOS ANGELES, June 23 /PRNewswire/ -- Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the South African Medicines Control Council has granted approval for a Phase II study in 30... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1264 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1264 Mon, 23 Jun 2008 13:00:00 +0000 Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination With Paclitaxel and Carboplatin CALGARY, Alberta, June 20 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1256 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1256 Fri, 20 Jun 2008 07:01:00 +0000 Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vaccine KVISTGÅRD, Denmark, June 19 /PRNewswire/ -- Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1247 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1247 Thu, 19 Jun 2008 08:17:00 +0000 Key Primary Resverlogix Objective Obtained SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today that it has completed the planned exploratory efficacy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1244 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1244 Wed, 18 Jun 2008 19:08:00 +0000 Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation LOS ANGELES, California, June 18 /PRNewswire/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1236 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1236 Wed, 18 Jun 2008 13:00:00 +0000 Nventa Develops Proprietary Vaccine Adjuvant SAN DIEGO, June 18 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR),... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1235 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1235 Wed, 18 Jun 2008 12:30:00 +0000 Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXl1717 STOCKHOLM, June 17 /PRNewswire/ -- Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1223 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1223 Tue, 17 Jun 2008 11:30:00 +0000 Oridion Announces Major Medical Research and Congress Presentations JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1219 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1219 Tue, 17 Jun 2008 06:00:00 +0000 Preterax(R) Prevents and Reverses Renal Disease in Type 2 Diabetics BERLIN, June 16 /PRNewswire/ -- New results of the ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation) trial have been presented today at the European... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1216 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1216 Mon, 16 Jun 2008 15:37:00 +0000 European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals MENLO PARK, California, June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1213 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1213 Mon, 16 Jun 2008 12:00:00 +0000 Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile LYON, France and SWIFTWATER, Pennsylvania, June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1211 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1211 Mon, 16 Jun 2008 09:57:00 +0000 VELCADE(R) (bortezomib) Data Highlights Superior Quantity and Quality Responses BEERSE, Belgium, June 14 /PRNewswire/ -- Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen- Cilag, today announced unprecedented results from a registration-enabling phase III... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1207 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1207 Sat, 14 Jun 2008 15:45:00 +0000 Treating Pain Effectively - New Study Results Confirm Improved Gastrointestinal Tolerability of Tapentadol PARIS and AACHEN, Germany, June 13 /PRNewswire/ -- Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1205 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1205 Fri, 13 Jun 2008 10:05:00 +0000 AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R)) AMSTERDAM, June 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has concluded enrollment and treated the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1201 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1201 Fri, 13 Jun 2008 06:00:00 +0000 UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound YOQNEAM, Israel and SAN RAMON, California, June 12 /PRNewswire/ -- UltraShape(R), a global leader in non-invasive fat reduction and body contouring, today announced the commencement of its pivotal... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1199 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1199 Thu, 12 Jun 2008 17:35:00 +0000 Axelar Receives Financing for a Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717 STOCKHOLM, Sweden, June 12 /PRNewswire/ -- Axelar AB today announced that the company has received financing from Östersjöstiftelsen (the Foundation for Baltic and East European Studies)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1197 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1197 Thu, 12 Jun 2008 11:30:00 +0000 New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel(R) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis MAIDENHEAD, England, June 12 /PRNewswire/ -- Data presented today show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1196 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1196 Thu, 12 Jun 2008 10:45:00 +0000 AmVac AG Begins Research Cooperation With Bayer Research Laboratory Inaugurated in Catania ZUG, Switzerland and CATANIA, Italy, June 12 /PRNewswire/ -- AmVac AG, a Swiss biopharmaceutical company based in Zug, is starting its first research cooperation program with Bayer Innovation GmbH... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1194 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1194 Thu, 12 Jun 2008 08:53:00 +0000 Mentice Initiates Collaboration With Pieter Stella as Clinical Advisor GOTHENBURG, June 12 /PRNewswire/ -- Mentice, a leading developer of medical simulation solutions, today announces collaboration with Dr. Pieter Stella as Clinical Advisor to Mentice. Dr Stella will... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1191 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1191 Thu, 12 Jun 2008 08:00:00 +0000 Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology SEATTLE and PARIS, June 12 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1189 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1189 Thu, 12 Jun 2008 06:00:00 +0000 The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine DEERFIELD, Illinois, June 11 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) announced publication in the June 12, 2008 issue of The New England Journal of Medicine (NEJM) of data demonstrating... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1188 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1188 Wed, 11 Jun 2008 22:36:00 +0000 New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients BASEL, Switzerland, June 11 /PRNewswire/ -- A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoetin... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1182 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1182 Wed, 11 Jun 2008 06:30:00 +0000 Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study COPENHAGEN, Denmark, June 10 /PRNewswire/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1181 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1181 Tue, 10 Jun 2008 20:26:00 +0000 Merck Serono's Rebif(R) Celebrates 10th Anniversary GENEVA, Switzerland, June 10 /PRNewswire/ -- Merck's Serono's Rebif(R) (interferon beta-1a) is celebrating its 10th anniversary this year. Since receiving approval for the treatment of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1176 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1176 Tue, 10 Jun 2008 07:30:00 +0000 New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS) INGELHEIM, Germany, June 10 /PRNewswire/ -- A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with Restless... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1174 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1174 Tue, 10 Jun 2008 07:00:00 +0000 UK & Israeli Scientists at London's UCL for Two Day Seminar - Biological Complexity: From Molecules To Systems LONDON, June 10 /PRNewswire/ -- Despite renewed threats of an academic boycott of Israeli academics, more than 200 scientists from leading UK and European universities will gather in London next week... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1175 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1175 Tue, 10 Jun 2008 07:00:00 +0000 AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response AMSTERDAM, The Netherlands, June 10 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1173 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1173 Tue, 10 Jun 2008 06:26:00 +0000 After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycaemic Control and Weight; DURATION-1 Presented at ADA 2008 SAN FRANCISCO, June 10 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a 52-week open... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1172 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1172 Tue, 10 Jun 2008 01:50:00 +0000 Solianis' Non-Invasive Glucose Monitor Tracks Blood Glucose in Outpatient Study ZURICH, June 9 /PRNewswire/ -- Solianis is conducting a study in which patients with diabetes are testing a preliminary functional model of the future device for non-invasive glucose monitoring.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1166 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1166 Mon, 09 Jun 2008 08:38:00 +0000 GRAZAX(R) Demonstrates Significant Reductions on Asthma Symptoms in Children BARCELONA, June 7 /PRNewswire/ -- ALK-Abelló today presented successful results from a new clinical trial, GT-12, designed to measure the impact of GRAZAX(R) on allergic rhinitis and allergic asthma.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1165 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1165 Sat, 07 Jun 2008 11:00:00 +0000 The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications SAN FRANCISCO, California, June 6 /PRNewswire/ -- New results from the world's largest ever study of diabetes treatments show that intensive blood glucose (sugar) control using modified... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1164 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1164 Fri, 06 Jun 2008 22:00:00 +0000 Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders HANOI, Vietnam, June 6 /PRNewswire/ -- QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1161 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1161 Fri, 06 Jun 2008 14:08:00 +0000 Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination With Paclitaxel and Carboplatin CALGARY, Canada, June 5 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1159 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1159 Thu, 05 Jun 2008 16:47:00 +0000 SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) CALGARY, Canada, June 5 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company dedicated to developing a portfolio of therapeutic proteins for metabolic and cardiovascular... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1156 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1156 Thu, 05 Jun 2008 12:00:00 +0000 Leading Blood Pressure Medication Diovan(R) With Diuretic Reduces Key Sign of Artery Ageing Which is Linked to Risk of Heart Attack and Stroke BASEL, Switzerland, June 5 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1153 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1153 Thu, 05 Jun 2008 07:15:00 +0000 Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus GENEVA, Switzerland, June 5 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its development partner ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today the initiation of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1152 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1152 Thu, 05 Jun 2008 07:00:00 +0000 Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant Congress EDMONTON, Canada, June 4 /PRNewswire/ -- Isotechnika Inc. today announces the successful results of the Phase 2b PROMISE trial which were presented by Dr. A. Osama Gaber, an investigator for the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1144 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1144 Wed, 04 Jun 2008 13:00:00 +0000 BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine MOUNTAIN VIEW, California, June 4 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. A Phase... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1142 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1142 Wed, 04 Jun 2008 09:59:00 +0000 Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial EDMONTON, Canada, June 3 /PRNewswire/ -- Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1138 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1138 Tue, 03 Jun 2008 12:00:00 +0000 Good News for the Summer: Beta-Carotene Helps to Protect Against Sunburn KAISERAUGST, Switzerland, June 3 /PRNewswire/ -- If "an apple a day keeps the doctor away", a carrot a day might help to keep the sun burn away. That is the conclusion of a recently published... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1136 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1136 Tue, 03 Jun 2008 09:30:00 +0000 Bavarian Nordic Enters Clinical Trials With Prostate Cancer Vaccine KVISTGÅRD, Denmark, June 3 /PRNewswire/ -- Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1135 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1135 Tue, 03 Jun 2008 08:36:00 +0000 ThromboGenics and BioInvent Report Positive Phase I Results for Anti-PlGF Cancer Therapeutic TB-403 LEUVEN, Belgium and LUND, Sweden, June 3 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) today reported that... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1134 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1134 Tue, 03 Jun 2008 07:00:00 +0000 Early Data Presented at ASCO Show Potential Of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments FRIMLEY, England, June 2 /PRNewswire/ -- http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1124 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1124 Mon, 02 Jun 2008 08:32:00 +0000 Bimatoprost / Timolol Fixed Combination Therapy Demonstrates Significantly Better IOP Control Over 12 Hours Compared to Latanoprost / Timolol Combination BERLIN, Germany, June 2 /PRNewswire/ -- Greater intra-ocular pressure (IOP) lowering benefit can be achieved for glaucoma patients treated with a fixed combination of bimatoprost and timolol... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1121 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1121 Mon, 02 Jun 2008 08:00:00 +0000 Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting CALGARY, Canada, June 2 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1119 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1119 Mon, 02 Jun 2008 07:01:00 +0000 Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer COLLEGEVILLE, Pennsylvania, June 2 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the INTORACT (Investigation of TORISEL And... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1118 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1118 Mon, 02 Jun 2008 06:00:00 +0000 Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites MUNICH, Germany and CHICAGO, May 31 /PRNewswire/ -- Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture-free survival in patients with malignant ascites, according... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1115 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1115 Sat, 31 May 2008 19:00:00 +0000 Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer FRIMLEY, England, May 31 /PRNewswire/ -- New data presented today showed that Zometa(R) (zoledronic acid) offered a significant anticancer benefit for premenopausal women with hormone-sensitive,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1114 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1114 Sat, 31 May 2008 15:15:00 +0000 Patients With Pancreatic Cancer can Benefit From Avastin(R) Plus Tarceva(R) BASEL, Switzerland, May 31 /PRNewswire/ -- Adding Avastin (bevacizumab) to a combination of Tarceva (erlotinib) and chemotherapy significantly improves the time patients with metastatic pancreatic... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1111 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1111 Sat, 31 May 2008 14:00:00 +0000 AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 AMSTERDAM, May 30 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that positive interim data from its pivotal clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1102 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1102 Fri, 30 May 2008 06:00:00 +0000 New Published Data Support Safety and Efficacy of RESOLOR(R) for Treatment of Chronic Constipation TURNHOUT, Belgium, May 29 /PRNewswire/ -- New phase III data for RESOLOR(R) (prucalopride) published today in The New England Journal of Medicine (NEJM) shows statistically and clinically significant... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1099 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1099 Thu, 29 May 2008 17:35:00 +0000 Movetis Files RESOLOR(R) With EMEA for the Indication of Chronic Constipation TURNHOUT, Belgium, May 29 /PRNewswire/ -- Movetis today announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1097 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1097 Thu, 29 May 2008 17:22:00 +0000 Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers COLLEGEVILLE, Pennsylvania, May 29 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1096 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1096 Thu, 29 May 2008 14:29:00 +0000 Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials EDMONTON, Canada, May 29 /PRNewswire/ -- Isotechnika Inc. announced today that voclosporin is positioned to enter a Phase 1 clinical trial as the drug utilized in the CINATRA(TM) Drug Coated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1095 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1095 Thu, 29 May 2008 14:00:00 +0000 Effective Management of Breakthrough Pain in Patients With Cancer Using Nycomed's Intranasal Fentanyl Spray TRONDHEIM, Norway, May 29 /PRNewswire/ -- Meaningful pain relief at 10 minutes following dosing with intranasal fentanyl spray among patients with cancer who experience breakthrough pain was reported... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1094 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1094 Thu, 29 May 2008 13:14:00 +0000 Genmab Announces Updates on Phase III Cancer Studies Summary COPENHAGEN, Denmark, May 29 /PRNewswire/ -- Genmab A/S (OMX: GEN) reports today that the last patient to be included in the planned interim analysis (N=132 patients) in the pivotal Phase III... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1093 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1093 Thu, 29 May 2008 12:23:00 +0000 Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield DOYLESTOWN, Pennsylvania, May 29 /PRNewswire/ -- Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1092 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1092 Thu, 29 May 2008 12:00:00 +0000 Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Würzburg, Germany AMSTERDAM, May 29 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR(TM) with Dr. Stephan Mielke and Professor... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1091 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1091 Thu, 29 May 2008 10:40:00 +0000 FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids TIRAT CARMEL, Israel, May 28 /PRNewswire/ -- InSightec Ltd. announced today that the U.S. Food and Drug Administration (FDA) cleared the company to conduct a clinical trial to evaluate the efficacy... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1080 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1080 Wed, 28 May 2008 13:00:00 +0000 Strong VC-trio Invest in PharmaSurgics Wound Healing Product GOTHENBURG, Sweden, May 28 /PRNewswire/ -- PharmaSurgics AB has received SEK 17 million to complete the preclinical development of their candidate drug (PXL01). The primary indication for PXL01 is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1078 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1078 Wed, 28 May 2008 12:00:00 +0000 First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer PARIS, May 27 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1075 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1075 Tue, 27 May 2008 18:00:00 +0000 Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine WASHINGTON DC, May 27 /PRNewswire/ -- Bavarian Nordic, the Danish-based biopharmaceutical company, has initiated a Phase I/II clinical study with its HIV vaccine candidate: MVA-BN(R) HIV... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1074 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1074 Tue, 27 May 2008 15:44:00 +0000 Isotechnika Reports Final Results of the PROMISE Trial EDMONTON, Canada, May 27 /PRNewswire/ -- Isotechnika Inc. (TSX:ISA) today announced positive results from the Phase 2b PROMISE trial which evaluated the Company's lead drug, voclosporin , in de novo... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1072 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1072 Tue, 27 May 2008 12:00:00 +0000 Bavarian Nordic Enters Clinical Trials With HIV Multiantigen Vaccine KVISTGÅRD, Denmark, May 27 /PRNewswire/ -- Bavarian Nordic has initiated Phase I/II clinical study with its HIV vaccine candidate: MVA-BN(R) HIV multiantigen. A Phase I/II safety and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1071 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1071 Tue, 27 May 2008 09:40:00 +0000 Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil BASINGSTOKE, England and CAMBRIDGE, Massachusetts, May 27 /PRNewswire/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that ELAPRASE(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1069 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1069 Tue, 27 May 2008 07:00:00 +0000 Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients CARLSBAD, California, May 24 /PRNewswire/ -- Ablation Frontiers, Inc. today announced that four presentations at the Heart Rhythm Society's 2008 Scientific Sessions reported positive early results... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1065 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1065 Sat, 24 May 2008 01:41:00 +0000 ThromboGenics Presents Further Results of the Vitreomacular Traction Trial (MIVI IIT) at the Euretina Annual Meeting in Vienna LEUVEN, Belgium, May 23 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular and eye diseases, today presented the six month follow up results from... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1063 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1063 Fri, 23 May 2008 17:56:00 +0000 New Evidence Advocates the use of Enbrel to Combat and Effectively Control the Debilitating Symptoms of Psoriasis ISTANBUL, Turkey, May 23 /PRNewswire/ -- New data from key clinical trials presented today at the 5th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Istanbul,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1061 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1061 Fri, 23 May 2008 08:30:00 +0000 Movetis Presents New Data at Digestive Disease Week SAN DIEGO, May 21 /PRNewswire/ -- Movetis NV, a European-based GI specialist pharmaceutical company, today announces that it has presented substantial new data from different studies this week at the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1054 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1054 Wed, 21 May 2008 23:30:00 +0000 Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission ABBOTT PARK, Illinois, May 21 /PRNewswire/ -- Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1053 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1053 Wed, 21 May 2008 17:15:00 +0000 Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap HILDEN, Germany, May 21 /PRNewswire/ -- Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1048 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1048 Wed, 21 May 2008 09:25:00 +0000 ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress BUENOS AIRES, Argentina, May 21 /PRNewswire/ -- Today at the World Congress of Cardiology (WCC), the press conference entitled "New Perspectives in Atrial Fibrillation Management" chaired by... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1046 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1046 Wed, 21 May 2008 06:00:00 +0000 Almirall and Forest Laboratories Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel Long-Acting Anticholinergic for the Treatment for COPD TORONTO, May 20 /PRNewswire/ -- Laboratorios Almirall, S.A. and Forest Laboratories, Inc. today presented results from four clinical trials assessing the efficacy and safety of aclidinium bromide, an... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1043 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1043 Tue, 20 May 2008 16:51:00 +0000 Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination SUNNYVALE, California, May 20 /PRNewswire/ -- BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1041 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1041 Tue, 20 May 2008 13:00:00 +0000 Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection from Cervical Disease than the Pap HILDEN, Germany, May 20 /PRNewswire/ -- Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1037 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1037 Tue, 20 May 2008 09:00:00 +0000 Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus SAN DIEGO, May 19 /PRNewswire/ -- Booth #2349 -- Digestive Disease Week -- BARRX Medical, Inc., a technology leader in the design and manufacture of medical devices for digestive diseases, today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1032 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1032 Mon, 19 May 2008 18:00:00 +0000 Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C PRINCETON, New Jersey, May 19 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) has nominated PSI-7851 as a lead development candidate for the treatment of chronic hepatitis C virus (HCV). PSI-7851 is... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1027 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1027 Mon, 19 May 2008 12:05:00 +0000 Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) FRIMLEY, England, May 20 /PRNewswire/ -- Tasigna(R) (nilotinib) is now available in the UK as a new option to treat adult patients who are intolerant or resistant to previous therapies for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1034 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1034 Mon, 19 May 2008 09:00:00 +0000 Case of Kiwi Guinea-Pig Girl 'Poisoned' by Sugar-Free Gum Adds Weight to Zsweet(R) Alternative DUBLIN, May 19 /PRNewswire/ -- A young lady from New Zealand who discovered that chewing sugar-free gum made her seriously ill has bravely agreed to act as a guinea-pig in an experiment in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1022 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1022 Mon, 19 May 2008 07:00:00 +0000 New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients BASEL, Switzerland, May 16 /PRNewswire/ -- Patients with breast or colorectal cancer, two of the world's most common cancers, can expect further treatment advances with Avastin(R) (bevacizumab) and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1013 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1013 Fri, 16 May 2008 02:00:00 +0000 Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation PARIS, May 15 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1006 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1006 Thu, 15 May 2008 17:45:00 +0000 Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents BARCELONA, Spain, May 15 /PRNewswire/ -- OrbusNeich today announced that multiple clinical data presentations in a symposium at EuroPCR 2008 support the use of the company's Genous Bio-engineered R... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1003 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1003 Thu, 15 May 2008 12:48:00 +0000 When ADHD Grows Up - New Study Supports Growing Body of Evidence for Adult ADHD HIGH WYCOMBE, England, May 15 /PRNewswire/ -- A new clinical study published today in Biological Psychiatry adds weight to the growing body of evidence that adults suffering from attention... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1002 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/1002 Thu, 15 May 2008 11:12:00 +0000 Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension APPENZELL, Switzerland, May 15 /PRNewswire/ -- Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/999 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/999 Thu, 15 May 2008 09:15:00 +0000 XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year BARCELONA, Spain, May 14 /PRNewswire/ -- Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II and SPIRIT III clinical trials demonstrated a clinically significant 51... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/996 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/996 Wed, 14 May 2008 16:56:00 +0000 Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C PRINCETON, New Jersey, May 14 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/991 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/991 Wed, 14 May 2008 12:05:00 +0000 New Data Support Routine Childhood Vaccination With PREVENAR in Europe MAIDENHEAD, England, May 14 /PRNewswire/ -- Data presented at the 26th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Graz, Austria, provide additional evidence... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/988 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/988 Wed, 14 May 2008 08:30:00 +0000 Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin CALGARY, Canada, May 14 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/987 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/987 Wed, 14 May 2008 07:01:00 +0000 XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years BARCELONA, Spain, May 13 /PRNewswire/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/981 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/981 Tue, 13 May 2008 14:30:00 +0000 Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents TEL AVIV, Israel, May 12 /PRNewswire/ -- Medinol is proud to announce that it has received CE Mark for its Presillion(TM) CoCr Coronary Stent, enabling physicians to treat coronary artery lesions... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/970 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/970 Mon, 12 May 2008 14:00:00 +0000 Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial SAN DIEGO, May 12 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of its ongoing Phase 1 clinical trial of its lead... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/968 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/968 Mon, 12 May 2008 12:30:00 +0000 Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio-engineered R stent, the world's first... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/951 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/951 Thu, 08 May 2008 13:00:00 +0000 Study Shows Prostate Cancer Gene 3 (PCA3) Correlates With Severity of Prostate Cancer LONDON, May 9 /PRNewswire/ -- A study published in the May 2008 issue of the peer-reviewed Journal of Urology demonstrates that the prostate cancer gene 3 (PCA3) can be used to detect and stratify... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/953 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/953 Thu, 08 May 2008 11:48:00 +0000 Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial FREDERICK, Maryland, May 7 /PRNewswire/ -- Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/947 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/947 Wed, 07 May 2008 19:24:00 +0000 Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections STAINES, England, May 7 /PRNewswire/ -- The European Medicines Agency (EMEA) has announced the marketing authorisation of Mycamine(R), Astellas Pharma Europe's treatment for invasive candidiasis,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/939 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/939 Wed, 07 May 2008 12:24:00 +0000 Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca SAN DIEGO, May 5 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/918 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/918 Mon, 05 May 2008 13:30:00 +0000 Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva(R) in the Treatment of Psoriasis Published in the British Journal of Dermatology GENEVA, Switzerland, May 5 /PRNewswire/ -- Final results of the first three-year prospective efficacy and safety study in moderate-to-severe chronic plaque psoriasis were recently published in the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/915 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/915 Mon, 05 May 2008 09:30:00 +0000 Biosimilar G-CSF: Cooperation on Three Continents. TORONTO, Canada, May 1 /PRNewswire/ -- A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/909 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/909 Thu, 01 May 2008 23:07:00 +0000 Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology HONG KONG, May 1 /PRNewswire/ -- The clinical impact of the first-ever pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, is the subject of a symposium at next month's 16th Annual... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/906 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/906 Thu, 01 May 2008 08:00:00 +0000 Merck Serono Announces Initiation of Phase II Clinical Trial of Atacicept in Relapsing Multiple Sclerosis GENEVA, Switzerland, April 30 /PRNewswire/ -- Merck Serono (NYSE: SRA), a division of Merck KGaA, Darmstadt, Germany, and its partner ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the initiation... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/898 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/898 Wed, 30 Apr 2008 11:00:00 +0000 Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat QUEBEC CITY, Canada, April 29 /PRNewswire/ -- At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/893 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/893 Tue, 29 Apr 2008 12:07:00 +0000 Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants ANN ARBOR, Michigan, April 28 /PRNewswire/ -- Terumo Heart, Inc. announced a presentation at the recent ISHLT meeting in Boston. The presentation entitled "Long Term Circulatory Support with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/887 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/887 Mon, 28 Apr 2008 14:05:00 +0000 Casual Games Scientifically Proven to Relieve Stress DUBLIN, Ireland and GREENVILLE, North Carolina, April 28 /PRNewswire/ -- East Carolina University reveals the results of a 6-month randomized, controlled study that confirms positive health benefits... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/886 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/886 Mon, 28 Apr 2008 14:00:00 +0000 Neuralstem Announces Issuance of Core Technology Patent in Europe ROCKVILLE, Maryland, April 28 /PRNewswire/ -- Stem cell company, Neuralstem, Inc., (Amex: CUR) announced today that the European Patent Office has granted Neuralstem a European patent... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/884 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/884 Mon, 28 Apr 2008 13:00:00 +0000 Gene Therapy Improves Vision in Patients with Congenital Retinal Disease PHILADELPHIA, April 27 /PRNewswire/ -- In a clinical trial at The Children's Hospital of Philadelphia, researchers from The University of Pennsylvania have used gene therapy to safely restore vision... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/878 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/878 Sun, 27 Apr 2008 21:31:00 +0000 Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC) MILAN, Italy, April 27 /PRNewswire/ -- At today's sessions of this, the final day of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), leading hepatologists... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/877 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/877 Sun, 27 Apr 2008 05:00:00 +0000 Potential New Oral Treatment May Revolutionise Management of Deadly Hepatitis C Virus WELWYN GARDEN CITY, England, April 27 /PRNewswire/ -- Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in combination with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/876 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/876 Sun, 27 Apr 2008 00:01:00 +0000 Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C BASEL, Switzerland, April 26 /PRNewswire/ -- Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) (peginterferon... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/875 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/875 Sat, 26 Apr 2008 17:22:00 +0000 Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study BASEL, Switzerland, April 26 /PRNewswire/ -- Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in combination with PEGASYS(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/874 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/874 Sat, 26 Apr 2008 17:15:00 +0000 New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible BASEL, Switzerland, April 26 /PRNewswire/ -- New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/873 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/873 Sat, 26 Apr 2008 08:15:00 +0000 Basic Science Discoveries Yield Progress in Hepatology MILAN, April 26 /PRNewswire/ -- At today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), experts reported advances in basic research that have... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/872 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/872 Sat, 26 Apr 2008 05:00:00 +0000 Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C PRINCETON, New Jersey and MILAN, Italy, April 25 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/870 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/870 Fri, 25 Apr 2008 16:30:00 +0000 Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120) INGELHEIM, Germany, April 25 /PRNewswire/ -- Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename VARGATEF(TM)) offers promising efficacy and is well tolerated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/934 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/934 Fri, 25 Apr 2008 15:30:00 +0000 Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120) INGELHEIM, Germany, April 25 /PRNewswire/ -- Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename VARGATEF(TM)) offers promising efficacy and is well tolerated... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/869 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/869 Fri, 25 Apr 2008 12:00:00 +0000 Important Progress Toward Control of Hepatitis B and C MILAN, April 25 /PRNewswire/ -- Scientists presenting at today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) reported encouraging findings... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/864 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/864 Fri, 25 Apr 2008 05:00:00 +0000 Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial SAN DIEGO, April 24 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/861 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/861 Thu, 24 Apr 2008 19:46:00 +0000 DART Study Results Demonstrate Dose Escalation With Enbrel(R)(etanercept) is Significantly Lower Than Other Commonly Used Anti-TNF Agents in Patients With Rheumatoid Arthritis(1) LIVERPOOL, England, April 24 /PRNewswire/ -- New pan-European data presented today at the British Society of Rheumatology's annual meeting in Liverpool demonstrate that patients treated with... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/855 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/855 Thu, 24 Apr 2008 10:00:00 +0000 Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy BASINGSTOKE, England and CAMBRIDGE, Massachusetts, April 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces the acquisition of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/853 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/853 Thu, 24 Apr 2008 07:00:00 +0000 Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema EVRY, France, April 24 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company today announced that it has successfully injected the first patient in a Phase I clinical trial... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/850 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/850 Thu, 24 Apr 2008 06:00:00 +0000 ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/851 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/851 Thu, 24 Apr 2008 06:00:00 +0000 More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL COLLEGEVILLE, Pennsylvania, April 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it is withdrawing its application for an extension to the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/848 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/848 Wed, 23 Apr 2008 22:50:00 +0000 MS Society Comments on Stem Cells Story LONDON, April 23 /PRNewswire/ -- With regard to Professor Charles ffrench-Constant's comments on stem cells and multiple sclerosis: Dr Laura Bell from the MS Society said: "These are exciting... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/843 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/843 Wed, 23 Apr 2008 14:14:00 +0000 First Human Implant of New Archus Orthopedics Facet Replacement System REDMOND, Washington, April 23 /PRNewswire/ -- Archus Orthopedics, Inc., announced today that it has successfully completed the first human implant of its TFAS-C(TM) system, the newest addition to the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/842 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/842 Wed, 23 Apr 2008 13:13:00 +0000 New Pill for Type 2 Diabetes Enhances Patients' Natural Body Process to Improve Blood Sugar Control FRIMLEY, England, April 23 /PRNewswire/ -- Vildagliptin, a new oral treatment for patients with type 2 diabetes is now available in the UK. Vildagliptin demonstrated additional reductions in HbA1c... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/840 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/840 Wed, 23 Apr 2008 07:30:00 +0000 Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/839 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/839 Wed, 23 Apr 2008 07:00:00 +0000 Dosing for RVX-208 Phase 1a Clinical Study Completed CALGARY, Canada, April 22 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/835 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/835 Tue, 22 Apr 2008 14:30:00 +0000 Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM) NOVATO, California, April 21 /PRNewswire/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/823 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/823 Mon, 21 Apr 2008 11:30:00 +0000 New Data Confirm Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome (RLS) INGELHEIM, Germany, April 17 /PRNewswire/ -- A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep disturbance, often the most troublesome symptom experienced... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/811 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/811 Thu, 17 Apr 2008 07:00:00 +0000 Encouraging Oral Therapy Trial Results LONDON, April 16 /PRNewswire/ -- Results of a study investigating an oral therapy for relapsing remitting multiple sclerosis (MS) have shown that continuous use of the drug, known as FTY720 or... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/808 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/808 Wed, 16 Apr 2008 16:58:00 +0000 Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma CALGARY, Canada, April 16 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James's University... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/804 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/804 Wed, 16 Apr 2008 11:30:00 +0000 Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS COPENHAGEN, April 15 /PRNewswire/ -- Summary: Genmab has announced that HuMax-EGFr (zalutumumab) inhibits epidermal growth factor receptor signaling by locking epidermal growth factor receptor... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/800 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/800 Tue, 15 Apr 2008 22:28:00 +0000 NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection HELSINGBORG, Sweden, April 15 /PRNewswire/ -- NOLabs AB, the Swedish medtech company focusing on developing innovative Nitric Oxide-containing medical devices, today reported that it has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/794 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/794 Tue, 15 Apr 2008 10:11:00 +0000 Clinically Proven Treatment Offers Help to Rosacea Sufferers DUBLIN, April 15 /PRNewswire/ -- It is commonly known that many children get facial rashes, while teenagers tend to have acne - but as a person ages, their skin is supposed to clear up. However,... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/793 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/793 Tue, 15 Apr 2008 09:00:00 +0000 Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial CALGARY, Canada, April 14 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/790 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/790 Mon, 14 Apr 2008 18:37:00 +0000 Revolutionary New Centre Transforms the Diagnosis of Heart Disease LONDON, April 14 /PRNewswire/ -- World renowned cardiologist and Medical Director of The British Cardiac Research Trust (BCRT), Professor Avijit Lahiri, today announced the launch of a new Clinical... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/776 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/776 Mon, 14 Apr 2008 00:01:00 +0000 Status of the E2007 (perampanel) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications TOKYO, Japan, April 11 /PRNewswire/ -- E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/768 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/768 Fri, 11 Apr 2008 07:06:00 +0000 Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide ISTANBUL, Turkey, April 10 /PRNewswire/ -- Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi-national study that will focus on the management of osteoporosis across the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/760 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/760 Thu, 10 Apr 2008 00:01:00 +0000 Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial CALGARY, Canada, April 9 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced positive interim results from its U.K. combination REOLYSIN(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/757 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/757 Wed, 09 Apr 2008 17:06:00 +0000 ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke LEUVEN, Belgium, April 9 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today that it has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/751 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/751 Wed, 09 Apr 2008 06:00:00 +0000 MS Society Responds to Announcement That Caffeine May Play Beneficial Role in MS LONDON, April 7 /PRNewswire/ -- Scientists have today announced that mice given the equivalent of six to eight cups of coffee a day were protected from developing the animal model for multiple... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/742 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/742 Mon, 07 Apr 2008 20:45:00 +0000 Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach LONDON, April 7 /PRNewswire/ -- Silence Therapeutics plc (AIM:SLN) Europe's leading RNAi-focused biotechnology company, today comments on two recent journal articles: Nature(1) "Sequence-and... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/735 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/735 Mon, 07 Apr 2008 07:00:00 +0000 UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting YOQNEAM, Israel and SAN RAMON, California, April 3 /PRNewswire/ -- Results of an independent multi-treatment clinical study of the UltraShape(R) Contour I, the first clinically proven non-invasive... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/725 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/725 Thu, 03 Apr 2008 12:00:00 +0000 Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure CHICAGO, April 2 /PRNewswire/ -- Final six-month, follow-up patient data presented yesterday during the late-breaking clinical trial sessions at the American College of Cardiology, suggest MyoCell(R)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/661 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/661 Wed, 02 Apr 2008 09:00:00 +0000 Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease EINDHOVEN, the Netherlands, April 1 /PRNewswire/ -- The Center for Translational Molecular Medicine (CTMM) - a Dutch public-private partnership committed to the research and development of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/656 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/656 Tue, 01 Apr 2008 12:12:00 +0000 ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) LEUVEN, Belgium, April 1 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, today announces that it has... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/652 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/652 Tue, 01 Apr 2008 06:00:00 +0000 Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study SAN DIMAS, California, March 31 /PRNewswire/ -- While molecular biologists and news reporters present jaw-dropping evidence that a red wine molecule called resveratrol may usher in the advent of... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/650 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/650 Mon, 31 Mar 2008 22:54:00 +0000 New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes CHICAGO, March 31 /PRNewswire/ -- New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS(R) (pioglitazone HCl)... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/647 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/647 Mon, 31 Mar 2008 18:01:00 +0000 First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study LONDON, March 31 /PRNewswire/ -- CRESTOR(TM) (rosuvastatin) is the only statin to show regression of coronary atherosclerosis in a major clinical study. That result, which was based on intravascular... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/644 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/644 Mon, 31 Mar 2008 16:00:00 +0000 Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event INGELHEIM, Germany, March 31 /PRNewswire/ -- The results of the landmark ONTARGET(R) Trial have proven that telmisartan, brand name MICARDIS(R), a modern angiotensin II receptor blocker (ARB), is as... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/646 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/646 Mon, 31 Mar 2008 16:00:00 +0000 Synosia Starts Phase II Efficacy Trial for Rufinamide BASEL, Switzerland, March 31 /PRNewswire/ -- Synosia Therapeutics today announced the start of a multi-site, Phase II clinical trial to evaluate the efficacy of rufinamide (SYN-111), a sodium channel... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/635 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/635 Mon, 31 Mar 2008 06:00:00 +0000 New Studies Confirm the Benefits of Dapoxetine as a Treatment of Premature Ejaculation European Association of Urology (EAU), MILAN, March 27 /PRNewswire/ -- New data presented for the first time today at EAU demonstrate the benefits for men with premature ejaculation (PE) and their... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/629 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/629 Thu, 27 Mar 2008 12:48:00 +0000 SemBioSys Initiates Toxicology Study for Safflower-Produced Insulin CALGARY, Canada, March 26 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/615 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/615 Wed, 26 Mar 2008 11:00:00 +0000 New Study Backs use of Gene-Based Urine Test in Prostate Cancer LONDON, March 19 /PRNewswire/ -- New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology(1) support the use of PROGENSA PCA3 as a tool for diagnosing prostate... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/595 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/595 Wed, 19 Mar 2008 11:10:00 +0000 Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe STOCKHOLM, Sweden, March 19 /PRNewswire/ -- Diamyd Medical announced today that the Swedish Medical Products Agency (MPA) has approved the Company's application to commence Phase III studies with the... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/592 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/592 Wed, 19 Mar 2008 10:15:00 +0000 Aegera Initiates Phase 1 Clinical Trial of AEG33773 - a Small Molecule in Development for Diabetic Neuropathic Pain MONTREAL, March 18 /PRNewswire/ -- Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/590 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/590 Tue, 18 Mar 2008 14:16:00 +0000 ALK-Abell, the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children HORSHOLM, Denmark, March 17 /PRNewswire/ -- ALK-Abelló yesterday presented successful Phase III clinical study results with GRAZAX(R) in children at the American Academy of Allergy, Asthma &... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/584 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/584 Mon, 17 Mar 2008 10:00:00 +0000 ALK-Abell, the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children HORSHOLM, Denmark, March 17 /PRNewswire/ -- - Results Show Highly Significant Effect on Rhinoconjunctivitis (Hay Fever) and Asthma Symptoms in Children from age 5 to 16 Years-old http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/716 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/716 Mon, 17 Mar 2008 10:00:00 +0000